[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 158
1. Hsiao HH, Liu YC, Tsai HJ, Tsai KB, Cheng YJ, Chou SH, Chong IW, Yang WC, Liu TC, Lin SF: Poor outcomes in patients with primary malignant mediastinal germ-cell tumors. Kaohsiung J Med Sci; 2005 Dec;21(12):561-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poor outcomes in patients with primary malignant mediastinal germ-cell tumors.
  • Primary mediastinal germ-cell tumors (GCTs) without gonadal involvement are rare and can be divided into benign mature teratoma and malignant seminoma or nonseminoma.
  • We describe our experience of malignant mediastinal GCTs and compare the presentations and outcome with those of benign teratomas.
  • Two patients died, one with extended pulmonary metastasis and the other with relapsed disease and high levels of tumor markers.
  • Compared with the nine cases of benign teratomas, the four malignant GCTs showed overwhelming male dominance, advanced symptoms at presentation, and poor outcome.
  • These cases highlight the important role of disease staging and tumor-marker levels in malignant GCTs, and suggest that new treatment strategies for malignant GCTs await further investigation.
  • [MeSH-major] Mediastinal Neoplasms / therapy. Neoplasms, Germ Cell and Embryonal / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16670048.001).
  • [ISSN] 1607-551X
  • [Journal-full-title] The Kaohsiung journal of medical sciences
  • [ISO-abbreviation] Kaohsiung J. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


2. Chen YS, Kuo JY, Chin TW, Wei CF, Chen KK, Lin AT, Chang LS: Prepubertal testicular germ cell tumors: 25-year experience in Taipei Veterans General Hospital. J Chin Med Assoc; 2008 Jul;71(7):357-61
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prepubertal testicular germ cell tumors: 25-year experience in Taipei Veterans General Hospital.
  • The purpose of this study was to focus on prepubertal males in an attempt to evaluate clinical features and optimal management among various testicular germ cell tumors with long-term follow-up.
  • METHODS: We retrospectively reviewed the records of children younger than 12 years of age with primary testicular germ cell tumors between February 1981 and December 2005 at Taipei Veterans General Hospital.
  • Of the 29 patients with yolk sac tumor, 26 (89.7%) were diagnosed as stage I, 1 (3.4%) as stage III, and 2 (7.0%) as stage IV.
  • One patient initially with stage III yolk sac tumor and 2 patients with stage IV yolk sac tumor were also treated with chemotherapy.
  • Eventually, 1 patient with stage IV yolk sac tumor died due to tumor progression; the remaining 28 patients with yolk sac tumor all survived without tumor relapse after appropriate treatment.
  • In the 5 patients with teratomas, there was no tumor relapse after radical orchiectomy with a mean follow-up time of 139.1 months.
  • The 5-year survival rates for yolk sac tumor and teratomas were 96.5% and 100%, respectively.
  • CONCLUSION: The most common prepubertal malignant testicular tumor is yolk sac tumor, and the most common benign testicular tumor is teratoma.
  • Children with testicular germ cell tumors have excellent long-term survival rates after appropriate treatment.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / therapy. Testicular Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18653399.001).
  • [ISSN] 1726-4901
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


3. Leseur J, Trivin F, Dupont-Bière E, Boucher E, Kerbrat P, Raoul JL: [Hemoperitoneum secondary to spontaneous rupture of metastatic liver of a testicular germ cell tumor]. Gastroenterol Clin Biol; 2007 Dec;31(12):1150-2
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hemoperitoneum secondary to spontaneous rupture of metastatic liver of a testicular germ cell tumor].
  • We report a case of hemoperitoneum secondary to a spontaneous rupture of liver metastases of a testicular germ cell cancer.
  • In clinical practice, some aetiologies must be considered in case of spontaneous hemoperitoneum, mainly rupture of liver tumors: hepatocellular carcinoma or unfrequently benign tumors; the rupture of a metastase is very uncommon.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18176377.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


Advertisement
4. Ulbright TM: Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues. Mod Pathol; 2005 Feb;18 Suppl 2:S61-79
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues.
  • Gonadal germ cell tumors continue to be the cause of diverse, diagnostically challenging issues for the pathologist, and their correct resolution often has major important therapeutic and prognostic implications.
  • Within the teratoma group, there is strong evidence that ovarian and prepubertal testicular teratomas are derived from benign germ cells, a pathogenesis that likely applies also to the rare dermoid cysts and uncommon epidermoid cysts of the testis.
  • In contrast, postpubertal testicular teratomas derive from malignant germ cells, specifically representing differentiation within a preexistent nonteratomatous cancer.
  • As expected, given the foregoing, teratomas in boys are clinically benign, whereas in postpubertal males they are malignant, independent of their degree of immaturity.
  • When uncommon somatic-type malignancies (usually squamous cell carcinoma) occur in mature cystic teratomas of the ovary, this is a de novo form of malignant transformation; similar tumors in the testis, a very rare event, represent overgrowth of teratomatous elements that originated from malignant, nonteratomatous germ cell tumors and, therefore, had previously undergone malignant transformation.
  • Germinomas may have several unusual features in each gonad; these include microcystic arrangements that suggest yolk sac tumor, tubular patterns that mimic Sertoli cell tumor, apparent increased cytological atypia that causes concern for embryonal carcinoma, and prominent syncytiotrophoblast giant cells that suggest choriocarcinoma.
  • A newly recognized aspect of this tumor is the propensity for some to be relatively monomorphic, making them apt to be mistaken for usual seminoma or embryonal carcinoma, although the characteristic polymorphic appearance in some foci, absence of intratubular germ cell neoplasia, unclassified type, and immunohistochemical stains should prevent this error.
  • Yolk sac tumor continues to be confused occasionally with clear cell carcinoma of the ovary.
  • The usually younger age of patients with yolk sac tumors helps with the differential considerations with the nongerm cell tumors, as do other clinical and microscopic features and selected immunohistochemical stains.
  • Syncytiotrophoblast cells alone, admixed with other forms of germ cell tumor, still are confused with choriocarcinoma, but this phenomenon, which is much more frequent than choriocarcinoma, lacks the plexiform arrangement of different trophoblast cell types that typifies the latter.
  • Mixed germ cell tumors (which may show almost any combination of components) are common in the testis but rare in the ovary.
  • A separately categorized, rare form of mixed germ cell tumor seen in both gonads is the polyembryoma.
  • It is perhaps the most photogenic of all gonadal germ cell tumors and is also intriguing because of its distinctive, organized arrangement of yolk sac tumor and embryonal carcinoma elements and recapitulation of very early embryonic development, even to the extent of having in its fundamental unit, the embryoid body, a miniature yolk sac, and amniotic cavity.
  • Embryoid bodies are also common as a minor component of many mixed germ cell tumors, particularly in the testis, and the diffuse embryoma is another variant that has a particular arrangement of yolk sac tumor and embryonal carcinoma elements.
  • Regression of gonadal germ cell tumors is a phenomenon restricted to the testis, for unknown reasons.
  • These so-called 'burnt-out' germ cell tumors can be recognized by a distinctive constellation of findings, including sometimes minor foci of residual recognizable germ cell neoplasia, a well-defined zone of scarring (often having residual ghost tubules), associated lymphoplasmacytic infiltrate, intratubular calcification and, in about 50%, of in situ germ cell neoplasia.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / pathology. Ovarian Neoplasms / pathology. Testicular Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15761467.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / KRT7 protein, human; 0 / Keratin-7; 0 / Organic Cation Transport Proteins; 0 / solute carrier family 22 (organic cation transporter), member 3; 68238-35-7 / Keratins; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Number-of-references] 132
  •  go-up   go-down


5. Fakhr IM, Khalil el-SA, El-Baradie TS, Shaalan MA, Shalaby LM, Nassif SL, Farahat IG: The role of surgical management in pediatric germ cell tumors (GCTs), NCI case series. J Egypt Natl Canc Inst; 2008 Mar;20(1):70-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of surgical management in pediatric germ cell tumors (GCTs), NCI case series.
  • PURPOSE: To review the experience of a tertiary referral center in pediatric germ cell tumors (GCTs) in the last 8 years and to investigate the impact of surgery and site of disease on prognosis.
  • PATIENTS AND METHODS: We retrospectively analyzed the cases of pediatric germ cell tumors at National Cancer Institute over an 8 years period.
  • One patient with benign GCT was excluded during analysis of the results.
  • Yolk sac tumor and malignant teratoma were the commonest histologic subtypes in our series.
  • CONCLUSION: The initial surgical approach to malignant GCTs at all sites should be complete resection when possible; the morbidity of extensive surgical resection should be weighed carefully against the good tumor control with chemotherapy.
  • The site of primary disease plays a role in the prognosis of pediatric germ cell tumors with the extragonadal pelvic tumors being the worst regarding resectability.
  • Good tumor response can be achieved with surgery and chemotherapy even for advanced stage and metastatic disease.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / surgery
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Child. Child, Preschool. Female. Humans. Infant. Lymphatic Metastasis. Male. Neoplasm Staging. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19847284.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  •  go-up   go-down


6. Khalid M, Malik N, Salauddin MA, Rashid M: Concomitant bilateral testicular epidermoid cysts. Saudi Med J; 2008 Jun;29(6):907-9
MedlinePlus Health Information. consumer health - Testicular Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epidermoid cyst of the testis is a rare benign germ cell tumor, comprising 1-2% of all resected benign testicular masses.
  • The fact that they are completely benign makes them amenable to treatment by local excision, thereby saving patient from orchidectomy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18521477.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


7. Rim SY, Kim SM, Choi HS: Struma ovarii showing clinical characteristics of ovarian malignancy. Int J Gynecol Cancer; 2005 Nov-Dec;15(6):1156-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Struma ovarii is a rare form of ovarian neoplasm, composed entirely or predominantly of thyroid tissue and generally a benign germ cell tumor of the ovary.
  • We experienced a rare case of a postmenopausal woman with benign struma ovarii associated with massive ascites, a complex pelvic mass.
  • No recurrence of the ascites or of the tumor has been observed during the 10-month follow-up.
  • [MeSH-major] Biomarkers, Tumor / blood. CA-125 Antigen / blood. Ovarian Neoplasms / pathology. Struma Ovarii / pathology. Teratoma / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343201.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen
  •  go-up   go-down


8. Azurmendi Arín I, Llarena Ibarguren R, Rodríguez JG, Olano Grasa I, Cantón Aller E, Pertusa Peña C: [Sertoli cell malignant tumor]. Arch Esp Urol; 2008 Sep;61(7):834-7
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Sertoli cell malignant tumor].
  • [Transliterated title] Tumor de células de Sertoli maligno.
  • OBJECTIVE: We report a new case of Sertoli cell testicular tumor with malignant characteristics.
  • METHODS: 77 year-old male patient, suffering a general wasting syndrome presenting with a left solid testicular mass with the diagnosis of malignant Sertoli cell tumor after orchyectomy, without local, regional or distant dissemination, and a benign outcome after 18 months of follow-up.
  • RESULTS: Sertoli cell tumor or androblastoma is classified as non-germ cell tumor derived from the stroma of the sexual cords.
  • There are three types depending on its cellular composition: calcified big cell, sclerotic cell, and the most frequent of all, the classic type.
  • CONCLUSIONS: Being the Sertoli cell testicular tumor rare, its malignant type is even rarer, accounting for not more than 10% of all.
  • [MeSH-major] Sertoli Cell Tumor. Testicular Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18972923.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


9. De Backer A, Madern GC, Oosterhuis JW, Hakvoort-Cammel FG, Hazebroek FW: Ovarian germ cell tumors in children: a clinical study of 66 patients. Pediatr Blood Cancer; 2006 Apr;46(4):459-64
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian germ cell tumors in children: a clinical study of 66 patients.
  • BACKGROUND: Ovarian germ cell tumors are rare in childhood.
  • The aim of this study is to review clinical presentation, management, and outcome in a two-center series of girls with ovarian germ cell tumor.
  • PROCEDURE: The records of 66 patients (median age 9 years) with histologically proven ovarian germ cell tumor (either benign or malignant), treated over a 44-year-span, were reviewed.
  • Sixteen patients had an emergency operation for tumor torsion.
  • Surgical removal of the tumor with or without the ovary and/or adnex was the sole treatment in 55 patients, chemotherapy was administered in 10 and radiotherapy + chemotherapy in one.
  • CONCLUSIONS: With a recurrence rate of 4.5% and a mortality rate of 3%, this series confirms the excellent prognosis for girls with ovarian germ cell tumor (GCT).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms, Germ Cell and Embryonal / drug therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Magnetic Resonance Imaging. Neoplasm Staging. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16206211.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


10. Wolff AL, Ladd AP, Kumar M, Gunderman RB, Stevens J: Pseudo-Meigs syndrome secondary to ovarian germ cell tumor. J Pediatr Surg; 2005 Apr;40(4):737-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudo-Meigs syndrome secondary to ovarian germ cell tumor.
  • Surgical resection of the mass found a stage Ic malignant mixed germ cell tumor of the ovary.
  • The pleural effusion and ascites were benign and resolved spontaneously after complete resection of the tumor, which is characteristic of a pseudo-Meigs syndrome.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / complications. Neoplasms, Germ Cell and Embryonal / surgery. Ovarian Neoplasms / complications. Ovarian Neoplasms / surgery

  • Genetic Alliance. consumer health - Ovarian germ cell tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15852294.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Bahrami A, Ro JY, Ayala AG: An overview of testicular germ cell tumors. Arch Pathol Lab Med; 2007 Aug;131(8):1267-80
SciCrunch. KEGG: Data: Disease Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An overview of testicular germ cell tumors.
  • CONTEXT: More than 90% of testicular neoplasms originate from germ cells.
  • Testicular germ cell tumors (GCTs) are a heterogeneous group of neoplasms with diverse histopathology and clinical behavior.
  • Unclassified intratubular germ cell neoplasia is the precursor of all GCTs, excluding spermatocytic seminoma and infantile/prepubertal GCTs.
  • Spermatocytic seminoma, a tumor of elderly men, typically has an indolent clinical behavior, but rarely it undergoes sarcomatous transformation associated with an aggressive behavior.
  • Most patients with prepubertal yolk sac tumor, the most common pediatric GCT, have stage I disease at presentation.
  • Teratomas in children regardless of maturity and dermoid cysts in adults are benign; in contrast, teratomas in adults have a malignant behavior.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Humans. Immunohistochemistry. Male. Prognosis. World Health Organization

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17683189.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 154
  •  go-up   go-down


12. Scolozzi P, Marret N, Bouzourene H, Luthi F, Bauer J, Jaques B, Lombardi T: Mixed testicular germ cell tumor presenting as metastatic pure choriocarcinoma involving the maxillary gingiva. J Oral Pathol Med; 2006 Oct;35(9):579-81
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed testicular germ cell tumor presenting as metastatic pure choriocarcinoma involving the maxillary gingiva.
  • Because of their unremarkable clinical appearance, they can be difficult to distinguish from more common gingival hyperplastic or reactive lesions, such as pyogenic granuloma, peripheral giant cell granuloma, and peripheral ossifying granuloma.
  • We are reporting here an unusual case of a 36-year-old man with a mixed testicular germ cell tumor presenting as a metastatic pure choriocarcinoma involving the maxillary gingiva, extending from the first left premolar to the left second maxillary molar, mimicking a 'benign looking' gingival mass.
  • [MeSH-major] Choriocarcinoma / secondary. Gingival Neoplasms / secondary. Mixed Tumor, Malignant / secondary. Neoplasms, Germ Cell and Embryonal / secondary. Testicular Neoplasms

  • Genetic Alliance. consumer health - Choriocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16968241.001).
  • [ISSN] 0904-2512
  • [Journal-full-title] Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • [ISO-abbreviation] J. Oral Pathol. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


13. Kobayashi T, Kawakita M, Terachi T, Habuchi T, Ogawa O, Kamoto T: Significance of elevated preoperative alpha-fetoprotein in postchemotherapy residual tumor resection for the disseminated germ cell tumors. J Surg Oncol; 2006 Dec 1;94(7):619-23
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of elevated preoperative alpha-fetoprotein in postchemotherapy residual tumor resection for the disseminated germ cell tumors.
  • BACKGROUND AND OBJECTIVES: The purpose of the study is to determine the significance of elevated serum alpha-fetoprotein (AFP) in the setting prior to residual tumor resection (RTR) following chemotherapy for metastatic germ cell tumor in terms of the prediction of histology of the specimen and postoperative survival.
  • METHODS: We conducted a retrospective review of 68 patients undergoing RTR for metastatic nonseminomatous germ cell tumor or extragonadal germ cell tumor after at least a first-line chemotherapy.
  • Rates of presence of residual malignant cell in RTR specimen were similar between patients with normal AFP (7/28 or 25%) and with mildly elevated (10-30 ng/ml) AFP (3/11 or 27%).
  • It should be carefully considered individually whether a mild elevation of AFP after chemotherapy represents residual malignancy or benign pathogenesis.
  • [MeSH-major] Biomarkers, Tumor / blood. Chorionic Gonadotropin, beta Subunit, Human / blood. Neoplasms, Germ Cell and Embryonal / surgery. Testicular Neoplasms / surgery. alpha-Fetoproteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant. Child. Child, Preschool. Combined Modality Therapy. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm, Residual / blood. Neoplasm, Residual / pathology. Neoplasm, Residual / surgery. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 17111392.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / alpha-Fetoproteins
  •  go-up   go-down


14. Haasper C, Länger F, Rosenthal H, Knobloch K, Mössinger E, Krettek C, Bastian L: Coccydynia due to a benign notochordal cell tumor. Spine (Phila Pa 1976); 2007 Jun 15;32(14):E394-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coccydynia due to a benign notochordal cell tumor.
  • OBJECTIVE: To present a rare case of a notochordal cell tumor.
  • RESULTS: Histology revealed an intraosseous benign notochordal cell tumor.
  • This tumor represents a recently described notochordal cell proliferation biologically distinct from chordomas.
  • CONCLUSIONS: Overdiagnosis of these notochordal cell proliferations as chordomas may occur if clinicians and pathologists are unfamiliar with the spectrum of notochordal proliferations.
  • [MeSH-major] Coccyx. Low Back Pain / etiology. Neoplasms, Germ Cell and Embryonal / complications. Spinal Neoplasms / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17572612.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Uglialoro AD, Beebe KS, Hameed M, Benevenia J: A rare case of intraosseous benign notochordal cell tumor of the coccyx. Orthopedics; 2009 Jun;32(6):445

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case of intraosseous benign notochordal cell tumor of the coccyx.
  • An excisional biopsy revealed benign notochord cell tumor.
  • Due to the rarity of intraosseous benign notochordal cell tumors, it is essential to document and review this type of tumor.
  • Only 2 benign notochordal cell tumors involving the coccyx have been previously reported, both of which presented with the same clinical symptoms of chronic coccydynia as our patient, likely due to the location of the involved lesion.
  • The other leading diagnosis in our patient was chordoma, a malignant and locally aggressive neoplasm that is important to consider and exclude.
  • Although chordomas have been well characterized in the surgery, pathology, and radiology literature, the benign notochordal cell tumor is a relative newcomer.
  • [MeSH-major] Coccyx / surgery. Low Back Pain / etiology. Neoplasms, Germ Cell and Embryonal / diagnosis. Neoplasms, Germ Cell and Embryonal / surgery. Spinal Neoplasms / diagnosis. Spinal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19634813.001).
  • [ISSN] 1938-2367
  • [Journal-full-title] Orthopedics
  • [ISO-abbreviation] Orthopedics
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Tangjitgamol S, Hanprasertpong J, Manusirivithaya S, Wootipoom V, Thavaramara T, Buhachat R: Malignant ovarian germ cell tumors: clinico-pathological presentation and survival outcomes. Acta Obstet Gynecol Scand; 2010;89(2):182-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant ovarian germ cell tumors: clinico-pathological presentation and survival outcomes.
  • OBJECTIVE: To evaluate clinico-pathological features, treatment, survival, and prognostic factors of patients with malignant ovarian germ cell tumors.
  • POPULATION: Malignant ovarian germ cell tumor patients treated between January 1996 and December 2007.
  • Patients with malignant tumors arising from benign cystic teratoma were excluded.
  • Only preoperative tumor marker elevation was a significant poor prognostic factor for PFS.
  • CONCLUSIONS: Malignant ovarian germ cell tumors have a good prognosis with conservative surgical treatment.
  • Elevated preoperative serum tumor markers are a poor prognostic factor for PFS.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / mortality. Neoplasms, Germ Cell and Embryonal / pathology. Ovarian Neoplasms / mortality. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Biomarkers, Tumor / blood. Chemotherapy, Adjuvant. Child. Child, Preschool. Chorionic Gonadotropin, beta Subunit, Human / blood. Disease-Free Survival. Female. Humans. L-Lactate Dehydrogenase / blood. Neoplasm Recurrence, Local / pathology. Prognosis. Radiotherapy, Adjuvant. Survival Rate. Young Adult. alpha-Fetoproteins / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19961281.001).
  • [ISSN] 1600-0412
  • [Journal-full-title] Acta obstetricia et gynecologica Scandinavica
  • [ISO-abbreviation] Acta Obstet Gynecol Scand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / alpha-Fetoproteins; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


17. Hinz S, Magheli A, Weikert S, Schulze W, Krause H, Schrader M, Miller K, Kempkensteffen C: Deregulation of EZH2 expression in human spermatogenic disorders and testicular germ cell tumors. World J Urol; 2010 Oct;28(5):631-5
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deregulation of EZH2 expression in human spermatogenic disorders and testicular germ cell tumors.
  • INTRODUCTION: Enhancer of Zeste 2 (EZH2) is an epigenetic transcriptional repressor involved in cell cycle control and cell fate decisions.
  • Since these processes play key roles during intact spermatogenesis, deregulation of EZH2 expression may contribute to the development and progression of benign and malignant testicular diseases.
  • The objective of this study was to investigate the expression profile of EZH2 in testicular germ cell tumors (TGCT) and spermatogenic defects.
  • EZH2 tumor levels were not related to the histological TGCT subtype or clinical tumor stage.
  • [MeSH-major] Biomarkers, Tumor / metabolism. DNA-Binding Proteins / metabolism. Down-Regulation / physiology. Neoplasms, Germ Cell and Embryonal / metabolism. Spermatogenesis / physiology. Testicular Neoplasms / metabolism. Transcription Factors / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochim Biophys Acta. 2002 Jun 21;1602(2):151-61 [12020801.001]
  • [Cites] Int J Androl. 2004 Jun;27(3):161-5 [15139971.001]
  • [Cites] Hum Reprod. 1998 May;13(5):1230-4 [9647552.001]
  • [Cites] J Cell Biochem Suppl. 2001;Suppl 36:129-43 [11455578.001]
  • [Cites] Cell. 2003 Mar 7;112(5):599-606 [12628181.001]
  • [Cites] J Androl. 2007 Jul-Aug;28(4):466-80 [17287457.001]
  • [Cites] Stem Cells. 2007 Sep;25(9):2191-9 [17525233.001]
  • [Cites] Int J Androl. 2005 Aug;28(4):224-9 [16048634.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):268-73 [16330673.001]
  • [Cites] J Cancer Res Clin Oncol. 2008 Mar;134(3):331-6 [17694325.001]
  • [Cites] Mol Hum Reprod. 2007 Jan;13(1):33-43 [17114209.001]
  • [Cites] J Immunol. 2001 May 15;166(10 ):5925-34 [11342607.001]
  • [Cites] Cell. 2006 Apr 21;125(2):301-13 [16630818.001]
  • [Cites] Nature. 2002 Oct 10;419(6907):624-9 [12374981.001]
  • [Cites] J Pathol. 2008 Jun;215(2):175-83 [18393368.001]
  • [Cites] Hum Reprod. 1999 Sep;14 Suppl 1:82-96 [10573026.001]
  • [Cites] J Cell Physiol. 2008 Feb;214(2):295-300 [17786943.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1475-82 [10749107.001]
  • [Cites] Mutat Res. 2008 Dec 1;647(1-2):21-9 [18723033.001]
  • [Cites] Neoplasia. 2005 Nov;7(11):1011-9 [16331887.001]
  • [Cites] EMBO J. 2003 Oct 15;22(20):5323-35 [14532106.001]
  • (PMID = 20043168.001).
  • [ISSN] 1433-8726
  • [Journal-full-title] World journal of urology
  • [ISO-abbreviation] World J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Transcription Factors; EC 2.1.1.43 / EZH2 protein, human; EC 2.1.1.43 / Enhancer of Zeste Homolog 2 Protein; EC 2.1.1.43 / Polycomb Repressive Complex 2
  •  go-up   go-down


18. You YN, Leibovitch BC, Que FG: Hepatic metastasectomy for testicular germ cell tumors: is it worth it? J Gastrointest Surg; 2009 Apr;13(4):595-601
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic metastasectomy for testicular germ cell tumors: is it worth it?
  • BACKGROUND: Chemotherapy is highly effective for metastatic germ cell tumor (GCT), but experience with resection of hepatic metastases from GCT is limited.
  • Hepatic histology included: necrosis (33%), viable tumor (27%), mature teratoma (13%), and benign histology (27%).
  • Concomitant resection of extrahepatic disease (14 patients, 93%) found necrosis (53%), mature teratoma (27%), and viable tumor (13%).
  • At 8.2 years (mean) from resection, 11 patients (73%) were alive: five with no evidence of disease, two with elevated tumor marker only, and four with gross disease.
  • [MeSH-major] Hepatectomy. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Neoplasms, Germ Cell and Embryonal / secondary

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19190967.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. De Backer A, Madern GC, Hakvoort-Cammel FG, Oosterhuis JW, Hazebroek FW: Mediastinal germ cell tumors: clinical aspects and outcomes in 7 children. Eur J Pediatr Surg; 2006 Oct;16(5):318-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mediastinal germ cell tumors: clinical aspects and outcomes in 7 children.
  • BACKGROUND: Mediastinal germ cell tumors presenting during childhood are extremely rare.
  • This paper reports on the clinical presentations, method(s) of treatment, complications, results and outcomes in a series of children with mediastinal germ cell tumors.
  • METHODS: A retrospective chart review of 7 children treated between 1971 and 2001 for mediastinal germ cell tumor was carried out.
  • Four patients had histologically benign tumors (mature teratoma).
  • Their sole treatment consisted of complete surgical excision of the tumor and (part of) the thymus using either median sternotomy or left-sided thoracotomy.
  • Malignant tumors were observed in three patients (1 yolk sac tumor, 1 choriocarcinoma and 1 malignant teratoma).
  • The patient with yolk sac tumor survived; he is now in remission, 4 years after diagnosis.
  • CONCLUSIONS: Both this study and the literature review testify to the extreme rarity of mediastinal germ cell tumors in childhood.
  • Children with this type of tumor usually are severely symptomatic.
  • Histologically benign tumors carry an excellent prognosis provided surgical excision is complete.
  • [MeSH-major] Mediastinal Neoplasms / diagnosis. Mediastinal Neoplasms / surgery. Neoplasms, Germ Cell and Embryonal / diagnosis. Neoplasms, Germ Cell and Embryonal / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17160775.001).
  • [ISSN] 0939-7248
  • [Journal-full-title] European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift für Kinderchirurgie
  • [ISO-abbreviation] Eur J Pediatr Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


20. Kempkensteffen C, Hinz S, Krause H, Jager T, Köllermann J, Weikert S, Christoph F, Schostak M, Miller K, Schrader M: Expression of splicing variants of the inhibitor of apoptosis livin in testicular germ cell tumors. Tumour Biol; 2008;29(2):76-82
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of splicing variants of the inhibitor of apoptosis livin in testicular germ cell tumors.
  • The inhibitor of apoptosis family member livin is expressed in several neoplasms but is absent in most benign tissues.
  • Livin has therefore been evaluated as a diagnostic and prognostic marker and recently gained much attention as a target for tumor therapy.
  • We evaluated the expression of livin splicing variants in 131 testicular germ cell tumors (TGCT) compared to 20 normal testicular tissue samples using dual-color real-time RT-PCR and Western blot analysis.
  • Livin expression was strongly related to TGCT differentiation but not to clinical tumor stage and patient age.
  • The beta-variant was expressed in 67.5% of seminomas but only in 27.1% of nonseminomatous germ cell tumors (NSGCT).
  • [MeSH-major] Adaptor Proteins, Signal Transducing / genetics. Apoptosis / physiology. Gene Expression Regulation, Neoplastic / physiology. Inhibitor of Apoptosis Proteins / genetics. Neoplasm Proteins / genetics. Neoplasms, Germ Cell and Embryonal / genetics. Protein Splicing / genetics. Testicular Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel
  • (PMID = 18515985.001).
  • [ISSN] 1423-0380
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / BIRC7 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Neoplasm Proteins; 0 / Protein Isoforms
  •  go-up   go-down


21. Devouassoux-Shisheboran M, Deschildre C, Mauduit C, Berger G, Mejean-Lebreton F, Bouvier R, Droz JP, Fénichel P, Benahmed M: Expression of galectin-3 in gonads and gonadal sex cord stromal and germ cell tumors. Oncol Rep; 2006 Aug;16(2):335-40
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of galectin-3 in gonads and gonadal sex cord stromal and germ cell tumors.
  • The aim of our study was to investigate galectin-3 mRNA and protein expression in normal ovaries and testes as well as in a variety of 51 gonadal sex cord stromal and germ cell tumors, and two testicular seminomatous and non-seminomatous cell lines, using either real-time PCR or immunohistochemistry.
  • In human ovaries, galectin-3 is absent from granulosa cells, as well as from granulosa cell and Sertoli-Leydig cell tumors, and is not a useful marker in distinguishing granulosa cell from Sertoli-Leydig cell tumors.
  • In malignant testicular Sertoli cell tumors, the expression of galectin-3 is down-regulated while, in benign Leydig cell tumors, this expression is maintained, indicating the possible implication of this gene in the development of more aggressive testicular sex cord stromal tumors.
  • In contrast to sex cord stromal tumors, galectin-3 expression is up-regulated in testicular germ cell tumors.
  • By real-time PCR, we demonstrated a significant elevation of the galectin-3 mRNA level in non-seminomatous testicular germ cell tumors and cell line as compared to normal testes and seminomas (p=0.0432 and p=0.0247, respectively), indicating the possible role of this gene in the non-seminomatous differentiation of germ cell tumors.
  • [MeSH-major] Biomarkers, Tumor / analysis. Galectin 3 / analysis. Sertoli Cell Tumor / diagnosis. Sex Cord-Gonadal Stromal Tumors / diagnosis. Testicular Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16820912.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Galectin 3; 0 / RNA, Messenger; 0 / Receptors, Androgen
  •  go-up   go-down


22. Vaysse C, Delsol M, Carfagna L, Bouali O, Combelles S, Lemasson F, Le Mandat A, Castex MP, Pasquet M, Moscovici J, Guitard J, Pienkowski C, Rubie H, Galinier P, Vaysse P: Ovarian germ cell tumors in children. Management, survival and ovarian prognosis. A report of 75 cases. J Pediatr Surg; 2010 Jul;45(7):1484-90
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian germ cell tumors in children. Management, survival and ovarian prognosis. A report of 75 cases.
  • BACKGROUND/PURPOSE: The aims of this study were to evaluate survival and ovarian prognosis in patients treated for ovarian germ cell tumor (OGCT) and to propose a decision-making protocol.
  • Tumor characteristics were assessed by tumor markers, imaging, and pathology.
  • Tumors were benign in 58 cases and malignant in 17 cases.
  • The average of the largest diameter of benign OGCT was significantly lower than that of malignant OGCT (76.5 +/- 49 mm versus 169 +/- 54 mm, P < .0001).
  • Ovarian-sparing tumorectomy was carried out in 27 benign OGCT; 23 (85%) preserved ovaries were follicular.
  • CONCLUSIONS: In our series, both benign and malignant OGCTs have a good prognosis.
  • A 75-mm cutoff size is proposed as an important criterion to preoperatively differentiate between benign and malignant tumors.
  • In benign OGCT, ovarian-sparing tumorectomy leads to preserve ovaries in approximately 85% of cases, and in malignant OGCT, high survival rate has been obtained.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / surgery. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adolescent. Biomarkers, Tumor. Child. Child, Preschool. Female. France. Humans. Infant. Ovariectomy. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20638529.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


23. Mannisto S, Butzow R, Salonen J, Leminen A, Heikinheimo O, Heikinheimo M: Transcription factors GATA-4 and GATA-6, and their potential downstream effectors in ovarian germ cell tumors. Tumour Biol; 2005 Sep-Oct;26(5):265-73
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcription factors GATA-4 and GATA-6, and their potential downstream effectors in ovarian germ cell tumors.
  • Ovarian germ cell tumors (GCTs) are histologically heterogeneous neoplasms originating from activated germ cells, the oocyte stem cells.
  • These rare tumors often contain many different tissues mixed together, and malignant components are occasionally hidden within benign tissues thus complicating the diagnosis.
  • The reasons for the variable differentiation of germ cells are still largely unknown.
  • The fact that GATA-6 and HNF-4 are expressed exclusively in endodermal tissues indicates that these transcription factors play a role in the differentiation of germ cells towards the endodermal phenotype.
  • Analysis of the nuclear transcription factors in tumor tissue could serve as a new informative diagnostic tool for ovarian GCTs.
  • [MeSH-major] DNA-Binding Proteins / biosynthesis. Neoplasms, Germ Cell and Embryonal / genetics. Neoplasms, Germ Cell and Embryonal / physiopathology. Ovarian Neoplasms / genetics. Ovarian Neoplasms / physiopathology. Transcription Factors / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Cell Transformation, Neoplastic. Child. Female. GATA4 Transcription Factor. GATA6 Transcription Factor. Gene Expression Profiling. Hepatocyte Nuclear Factor 4. Humans. Middle Aged. Phenotype. Phosphoproteins / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 S. Karger AG, Basel.
  • (PMID = 16110260.001).
  • [ISSN] 1010-4283
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / GATA4 Transcription Factor; 0 / GATA6 Transcription Factor; 0 / GATA6 protein, human; 0 / Hepatocyte Nuclear Factor 4; 0 / Phosphoproteins; 0 / Transcription Factors
  •  go-up   go-down


24. Van Cauwelaert Rojas R, Ruiz-Tagle Phillips D, Meneses Ciuffardi M, Carrasco Troncoso AM, Aguirre Aguirre C: [Three cases of unusual non-germ cell tumors of the testicle]. Actas Urol Esp; 2007 Sep;31(8):923-7
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Three cases of unusual non-germ cell tumors of the testicle].
  • By describing 3 clinical cases of unusual testicular non germinal tumors, including an adenoma of the rete testis, an undifferenciated sex cord tumor and a mesothelioma of the tunica vaginalis, we make a literature review of the unusual testicular tumors and testicular apendix, including their incidence and management.
  • Also and as one of our conclusions, we expose the importance of the intraoperatory biopsy in the testicular cancer surgery, because even if it is infrecuent, the presence of this rare testicular tumors, in which if they are proven to be benign, the testicular unit could be preserved and the radical orquiectomy could be avoided.

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18020219.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


25. Ueda M, Toji E, Noda S: Germ line and somatic mutations of BRAF V599E in ovarian carcinoma. Int J Gynecol Cancer; 2007 Jul-Aug;17(4):794-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Germ line and somatic mutations of BRAF V599E in ovarian carcinoma.
  • It has been shown that ovarian low-grade serous carcinoma evolves out of a stepwise progression from benign serous cystadenoma to serous borderline tumor (SBT) to micropapillary serous carcinoma (MPSC), and that BRAF activation is a very early somatic event in the tumorigenesis.
  • We postulated that BRAF could be a SBT susceptibility gene, and investigated both germ line and somatic mutations of BRAF V599E in 104 ovarian cancer patients.
  • BRAF V599E mutation in histologic samples was found in 5 (24%) of 21 SBTs, 1 (33%) of 3 MPSCs, 1 (17%) of 6 endometrioid carcinomas, but not detected in 42 conventional serous carcinomas, 12 mucinous borderline tumors, 10 mucinous, and 10 clear-cell carcinomas.
  • We also found no BRAF V599E mutation in 101 normal healthy women and 10 well-established ovarian cancer cell lines.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Genetic Predisposition to Disease. Germ-Line Mutation. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17309670.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


26. De Backer A, Madern GC, Hazebroek FW: Retroperitoneal germ cell tumors: a clinical study of 12 patients. J Pediatr Surg; 2005 Sep;40(9):1475-81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retroperitoneal germ cell tumors: a clinical study of 12 patients.
  • PURPOSE: The aim of the study was to examine the clinical presentation, method(s) of treatment, complications, and results in newborns and infants with retroperitoneal germ cell tumors (GCTs).
  • Symptoms in these 8 boys and 4 girls were abdominal distension and a palpable upper abdominal mass, right-sided in 5, left-sided in 5, and central in 2; the tumor was usually big.
  • The patients with YSTs underwent surgical biopsy, followed by chemotherapy and excision of the remaining tumor and of the metastases.
  • No adjuvant treatment was administered in the patients with benign disease.
  • Nine survivors with benign tumor are disease-free between 1 and 30 years after surgery.
  • Surgical removal of the tumors appeared to be hazardous because of the extent of the tumor, the displacement and elongation of adjacent structures and organs, and/or the adhesion of the tumor to surrounding tissues; this resulted in several perioperative complications.
  • The long-term results are good, however, with 9 of 10 patients with benign tumors in good health after a mean follow-up of 12 years, and with the 2 patients with YST in remission for 6 and 5 years, respectively.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal. Retroperitoneal Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16150352.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Zynger DL, Dimov ND, Luan C, Teh BT, Yang XJ: Glypican 3: a novel marker in testicular germ cell tumors. Am J Surg Pathol; 2006 Dec;30(12):1570-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glypican 3: a novel marker in testicular germ cell tumors.
  • Glypican 3 (GPC3), a membrane-bound heparin sulfate proteoglycan, may play a role in promoting embryonic cell growth and differentiation.
  • However, the presence of the GPC3 protein in germ cell tumors has never been investigated.
  • The purpose of the study was to investigate the GPC3 expression in various histologic components of testicular germ cell tumors using immunohistochemistry and to assess its possible utility as a diagnostic marker.
  • All yolk sac tumor (24/24) and choriocarcinoma (7/7) components were immunoreactive for GPC3, whereas only 38% of teratomas with immature elements and 8% of embryonal carcinomas expressed GPC3.
  • There was no immunoreactivity in benign testicular tissue, intratubular germ cell neoplasia, seminomas (0/42), or teratomas with mature elements (0/20).
  • We conclude that the oncofetal protein GPC3 is a novel immunohistochemical marker in testicular germ cell tumors with differential expression in defined histologic subtypes.
  • Our findings suggest a possible role of GPC3 in tumor cell differentiation.
  • Furthermore, GPC immunostaining may be useful in the pathologic diagnosis of nonseminomatous germ cell tumors, particularly yolk sac tumor, and choriocarcinoma.
  • [MeSH-major] Glypicans / metabolism. Neoplasms, Germ Cell and Embryonal / metabolism. Testicular Neoplasms / metabolism
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor / analysis. Biomarkers, Tumor / metabolism. Fluorescent Antibody Technique, Indirect. Humans. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17122513.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPC3 protein, human; 0 / Glypicans
  •  go-up   go-down


28. Kesler KA, Wilson JL, Cosgrove JA, Brooks JA, Messiha A, Fineberg NS, Einhorn LH, Brown JW: Surgical salvage therapy for malignant intrathoracic metastases from nonseminomatous germ cell cancer of testicular origin: analysis of a single-institution experience. J Thorac Cardiovasc Surg; 2005 Aug;130(2):408-15
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical salvage therapy for malignant intrathoracic metastases from nonseminomatous germ cell cancer of testicular origin: analysis of a single-institution experience.
  • BACKGROUND: Cisplatin-based chemotherapy followed by surgical extirpation of residual benign disease represents the usual sequence of curative therapy for metastatic nonseminomatous germ cell cancer of testicular origin.
  • Occasionally, residual disease is malignant in the form of either a persistent nonseminomatous germ cell cancer tumor or degeneration into non-germ cell cancer.
  • METHODS: From 1981 through 2001, 438 patients with nonseminomatous germ cell cancer had operations to remove residual intrathoracic disease after cisplatin-based chemotherapy at Indiana University Hospital.
  • Surgical pathology demonstrated 84 patients with persistent nonseminomatous germ cell cancer tumors, 38 with degeneration into non-germ cell cancer, and 12 with both malignant pathologic categories.
  • CONCLUSIONS: Salvage thoracic surgery to remove malignant metastases from nonseminomatous germ cell cancer tumors of testicular origin can result in long-term survival in select patients.
  • [MeSH-major] Lung Neoplasms / therapy. Mediastinal Neoplasms / therapy. Neoplasms, Germ Cell and Embryonal / therapy. Testicular Neoplasms / therapy. Thoracic Surgical Procedures / methods
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Combined Modality Therapy. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16077406.001).
  • [ISSN] 0022-5223
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


29. Eifler JB Jr, King P, Schlegel PN: Incidental testicular lesions found during infertility evaluation are usually benign and may be managed conservatively. J Urol; 2008 Jul;180(1):261-4; discussion 265
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidental testicular lesions found during infertility evaluation are usually benign and may be managed conservatively.
  • PURPOSE: Hypoechoic lesions on scrotal ultrasonography are often considered germ cell tumors and radical orchiectomy is recommended.
  • Of the men 26% had a history of cryptorchidism and 3 patients had a history of testis tumor.
  • All men had tumor markers tested and the results were negative.
  • Of the remaining 18 patients 11 had lesions less than 5 mm in greatest diameter and all of these were confirmed to be benign.
  • All other patients with hyperechoic or heterogeneous areas on ultrasound with subsequent tissue diagnoses were found to have benign lesions.
  • CONCLUSIONS: Men with severe infertility who are found to have incidental testicular lesions and negative tumor markers, especially lesions less than 5 mm, may be initially observed with serial scrotal ultrasound examinations.


30. Passman C, Urban D, Klemm K, Lockhart M, Kenney P, Kolettis P: Testicular lesions other than germ cell tumours: feasibility of testis-sparing surgery. BJU Int; 2009 Feb;103(4):488-91
MedlinePlus Health Information. consumer health - Testicular Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Testicular lesions other than germ cell tumours: feasibility of testis-sparing surgery.
  • OBJECTIVE: To review all non-germ-cell testicular lesions presenting at our institution and to determine the feasibility of testis-sparing surgery for these patients.
  • Patients with atrophy, germ cell tumours, infection or torsion were excluded.
  • The study comprised men who had radical orchidectomy for suspected germ-cell tumour but had other final pathology, and those where testis-sparing surgery was attempted for a presumed benign lesion.
  • The lesions could be categorized as inflammatory (three hyalinized fibrosis, two sarcoidosis, one chronic inflammation), cystic (one epidermoid cyst, one unilocular cyst), benign neoplasms (two adenomatoid tumours, one Leydig cell tumour, one capillary haemangioma) or malignant neoplasms (one lymphoma).
  • In the other five, testis-sparing surgery was not attempted because the preoperative impression was that of a germ cell tumour.
  • CONCLUSION: Testis-sparing surgery might be possible if there is significant suspicion of a benign lesion.
  • [MeSH-minor] Adolescent. Adult. Aged. Feasibility Studies. Humans. Leydig Cell Tumor / pathology. Leydig Cell Tumor / surgery. Leydig Cell Tumor / ultrasonography. Male. Middle Aged. Neoplasms, Germ Cell and Embryonal / pathology. Neoplasms, Germ Cell and Embryonal / surgery. Retrospective Studies. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18793303.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


31. Zheng LW, Li FB, Liu RZ, Ji RG, Zhao ZW: [Clinical analysis of 87 cases of testicular tumor]. Zhonghua Nan Ke Xue; 2005 Jun;11(6):445-7
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 87 cases of testicular tumor].
  • OBJECTIVE: To improve the diagnosis and treatment of testicular tumor.
  • METHODS: Eighty-seven cases of testicular tumor were retrospectively studied.
  • RESULTS: Of the total number, 79 cases were pathologically diagnosed as germ cell tumor (90.1%), among which there were 44 cases of seminoma (55.7%) and 7 cases of benign tumor (8.1%).
  • Nonseminoma germ cell tumor (NSGCT) was found mainly among those under 5 and from 18 to 40 years of age, while seminoma chiefly among those beyond 17, and testis tumor was rare among those between 5 and 17 years old (1 case only).
  • (1) Testicular tumors are mostly germ cell tumors. (2) NSGCT develops mainly among those under the age of 5 and from 18 to 40. (3) Seminoma is rare in those under 18. (4) Testicular tumor rarely develops among those between 5 and 17 years old. (5)Three-year and 5-year survival rates for seminoma are higher than those for NSGCT.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / pathology. Testicular Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15999491.001).
  • [ISSN] 1009-3591
  • [Journal-full-title] Zhonghua nan ke xue = National journal of andrology
  • [ISO-abbreviation] Zhonghua Nan Ke Xue
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


32. Güney M, Oral B, Demir F, Ozsoy M, Kapucuoğlu N: Mucinous adenocarcinoma arising from the gastrointestinal epithelium in benign cystic teratoma of the ovary--case report. Eur J Gynaecol Oncol; 2006;27(3):304-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous adenocarcinoma arising from the gastrointestinal epithelium in benign cystic teratoma of the ovary--case report.
  • Benign cystic teratoma of the ovary (BCTO) is the most common ovarian germ cell tumor occurring predominantly in early adulthood.
  • Most benign cystic teratomas with malignant transformations are squamous cell carcinomas with just 6.8% being adenocarcinomas.

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16800267.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


33. Carmignani L, Colombo R, Gadda F, Galasso G, Lania A, Palou J, Algaba F, Villavicencio H, Colpi GM, Decobelli O, Salvioni R, Pizzocaro G, Rigatti P, Rocco F: Conservative surgical therapy for leydig cell tumor. J Urol; 2007 Aug;178(2):507-11; discussion 511
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conservative surgical therapy for leydig cell tumor.
  • PURPOSE: We performed a long-term evaluation of conservative surgical treatment of benign Leydig cell tumor.
  • Case files of all patients diagnosed with Leydig cell tumor and treated with conservative surgery were examined.
  • Patients underwent physical examination, hormone and tumor marker assays, scrotal and abdominal ultrasound, chest x-ray, and an endocrinological examination.
  • RESULTS: From 1987 to 2006, 22 patients with Leydig cell tumor underwent conservative surgery.
  • Three patients were monorchid after contralateral orchiectomy for inguinal hernia repair (1 patient, 28 years before surgery) and nonseminomatous germ cell tumor (2 patients, 1 month and 6 years before surgery).
  • Diagnosis after frozen section examination was Leydig cell tumor in 20 of 22 cases (91.0%).
  • Tumor markers were normal before and after surgery.
  • Followup was conducted for all patients every 3 to 6 months with physical examination, tumor markers, scrotal and abdominal ultrasound, chest x-ray.
  • CONCLUSIONS: When diagnosed early Leydig cell tumors present a favorable followup.
  • [MeSH-major] Leydig Cell Tumor / surgery. Testicular Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Diagnosis, Differential. Early Diagnosis. Humans. Male. Middle Aged. Neoplasm Staging. Orchiectomy. Retrospective Studies. Testis / pathology. Testis / surgery

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17561156.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


34. Nistal M, García-Cabezas MA, Castello MC, De Miguel MP, Regadera J: Age-related epididymis-like intratesticular structures: benign lesions of Wolffian origin that can be misdiagnosed as testicular tumors. J Androl; 2006 Jan-Feb;27(1):79-85
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Age-related epididymis-like intratesticular structures: benign lesions of Wolffian origin that can be misdiagnosed as testicular tumors.
  • The ELITSs are distinct from atrophic seminiferous tubules with a Sertoli cell-only pattern and from the benign glandular teratomatous component of an involution of a malignant testicular germ cell tumor, the so-called burn-out germ cell tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16400082.001).
  • [ISSN] 0196-3635
  • [Journal-full-title] Journal of andrology
  • [ISO-abbreviation] J. Androl.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


35. Kaur H, Bagga R, Saha SC, Gainder S, Srinivasan R, Adhya AK, Dhaliwal LK: Juvenile granulosa cell tumor of the ovary presenting with pleural effusion and ascites. Int J Clin Oncol; 2009 Feb;14(1):78-81
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Juvenile granulosa cell tumor of the ovary presenting with pleural effusion and ascites.
  • Juvenile granulosa cell tumor (GCT) is a rare tumor, and the majority (90%) are reported in the prepubertal or under-30-year age group, in contrast to the adult type, which is more common in the fifth decade.
  • Being solid tumors, they may be associated with ascites and pleural effusion (Meigs' syndrome), which resolve after surgical removal of the tumor.
  • Tumor markers for GCT are still investigational (inhibin) and of not much use in making a preoperative diagnosis, unlike in the case of germ cell tumors.
  • In the present patient, because of the association of Meigs' syndrome, a preoperative diagnosis of benign tumors such as fibroma/thecoma was also considered.
  • We report this rare tumor with an aim of reviewing the diagnosis and management from the reported literature.
  • [MeSH-major] Ascites / etiology. Granulosa Cell Tumor / pathology. Meigs Syndrome / pathology. Ovarian Neoplasms / pathology. Pleural Effusion, Malignant / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Singapore Med J. 2001 May;42(5):203-7 [11513057.001]
  • [Cites] Korean J Intern Med. 2005 Mar;20(1):105-9 [15906965.001]
  • [Cites] Am J Obstet Gynecol. 1999 Feb;180(2 Pt 1):323-7 [9988794.001]
  • [Cites] Obstet Gynecol. 1978 Dec;52(6):718-23 [733139.001]
  • [Cites] Gynecol Oncol. 1999 Apr;73(1):51-5 [10094880.001]
  • [Cites] Gynecol Oncol. 1995 Dec;59(3):405-8 [8522265.001]
  • [Cites] Gynecol Oncol. 2007 Feb;104(2):396-400 [17030354.001]
  • [Cites] Cancer. 1997 May 15;79(10):1951-5 [9149022.001]
  • [Cites] Gynecol Oncol. 2005 Jan;96(1):204-9 [15589602.001]
  • [Cites] Gynecol Oncol. 1999 Apr;73(1):35-41 [10094877.001]
  • [Cites] Am J Obstet Gynecol. 2004 Jul;191(1):366-7 [15295395.001]
  • [Cites] Gynecol Oncol. 1996 Mar;60(3):484-8 [8774662.001]
  • [Cites] N Engl J Med. 1989 Sep 21;321(12):790-3 [2770810.001]
  • [Cites] Gynecol Oncol. 1995 Mar;56(3):338-44 [7705666.001]
  • [Cites] Gynecol Oncol. 2006 Oct;103(1):31-4 [16537089.001]
  • (PMID = 19225930.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


36. Jang SI, Lee EJ, Hart PS, Ramaswami M, Pallos D, Hart TC: Germ line gain of function with SOS1 mutation in hereditary gingival fibromatosis. J Biol Chem; 2007 Jul 13;282(28):20245-55
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Germ line gain of function with SOS1 mutation in hereditary gingival fibromatosis.
  • Mutation of human SOS1 is responsible for hereditary gingival fibromatosis type 1, a benign overgrowth condition of the gingiva.
  • Here, we investigated molecular mechanisms responsible for the increased rate of cell proliferation in gingival fibroblasts caused by mutant SOS1 in vitro.
  • Additionally, we observed an increase in the magnitude and duration of ERK signaling in hereditary gingival fibromatosis gingival fibroblasts that was associated with phosphorylation of retinoblastoma tumor suppressor protein and the up-regulation of cell cycle regulators, including cyclins C, D, and E and the E2F/DP transcription factors.
  • These factors promote cell cycle progression from G(1) to S phase, and their up-regulation may underlie the increased gingival fibroblast proliferation observed.
  • Selective depletion of wild-type and mutant SOS1 through small interfering RNA demonstrates the link between mutation of SOS1, ERK signaling, cell proliferation rate, and the expression levels of Egr-1 and proliferating cell nuclear antigen.
  • [MeSH-minor] Cell Membrane / genetics. Cell Membrane / metabolism. Cell Membrane / pathology. Cells, Cultured. Cyclins / biosynthesis. E2F Transcription Factors / biosynthesis. Early Growth Response Protein 1 / biosynthesis. Early Growth Response Protein 1 / genetics. Extracellular Signal-Regulated MAP Kinases / metabolism. Humans. Phosphorylation. Proliferating Cell Nuclear Antigen / biosynthesis. Proliferating Cell Nuclear Antigen / genetics. Protein Processing, Post-Translational / genetics. Protein Transport / genetics. RNA, Small Interfering / genetics. RNA, Small Interfering / pharmacology. Retinoblastoma Protein / genetics. Retinoblastoma Protein / metabolism. Up-Regulation / genetics

  • Genetic Alliance. consumer health - Hereditary gingival fibromatosis.
  • Genetic Alliance. consumer health - Fibromatosis.
  • Genetics Home Reference. consumer health - SOS1 gene.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17510059.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclins; 0 / E2F Transcription Factors; 0 / EGR1 protein, human; 0 / Early Growth Response Protein 1; 0 / Proliferating Cell Nuclear Antigen; 0 / RNA, Small Interfering; 0 / Retinoblastoma Protein; 0 / SOS1 Protein; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases
  •  go-up   go-down


37. Esheba GE, Pate LL, Longacre TA: Oncofetal protein glypican-3 distinguishes yolk sac tumor from clear cell carcinoma of the ovary. Am J Surg Pathol; 2008 Apr;32(4):600-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncofetal protein glypican-3 distinguishes yolk sac tumor from clear cell carcinoma of the ovary.
  • Clear cell carcinoma (CCC) of the ovary is the surface epithelial neoplasm most often confused with primitive germ cell tumors, particularly yolk sac tumor (YST) and dysgerminoma.
  • Recent studies suggest that glypican-3 (GPC3), an oncofetal protein expressed in fetal liver and malignant tumors of hepatocytic lineage, is also expressed in germ cell tumors, particularly YST.
  • Tissue microarrays containing over 400 benign and malignant ovarian neoplasms, including 34 CCCs were stained with monoclonal GPC3 (clone 1G12, Biomosaics, Burlington, VT).
  • These arrays contained a wide assortment of ovarian surface epithelial neoplasms and sex cord stromal neoplasms, as well as germ cell tumors.
  • All but one YST (97%), including those associated with mixed germ cell tumor were positive for GPC3, whereas all teratomas and embryonal carcinomas were negative.
  • The syncytiotrophoblastic cells in the germ cell tumors and placental villi included in the arrays were also positive for GPC3.
  • [MeSH-major] Antigens, Neoplasm / analysis. Biomarkers, Tumor / analysis. Carcinoma / chemistry. Endodermal Sinus Tumor / chemistry. Glypicans / analysis. Ovarian Neoplasms / chemistry

  • Genetic Alliance. consumer health - Yolk sac tumor.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18277882.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / GPC3 protein, human; 0 / Glypicans; 0 / KRT7 protein, human; 0 / Keratin-7; 0 / alpha-Fetoproteins; 0 / oncofetal antigens
  •  go-up   go-down


38. Song JY, Chen KY, Kim SY, Kim MR, Ryu KS, Cha JH, Kang CS, MacLaughlin DT, Kim JH: The expression of Müllerian inhibiting substance/anti-Müllerian hormone type II receptor protein and mRNA in benign, borderline and malignant ovarian neoplasia. Int J Oncol; 2009 Jun;34(6):1583-91
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The expression of Müllerian inhibiting substance/anti-Müllerian hormone type II receptor protein and mRNA in benign, borderline and malignant ovarian neoplasia.
  • There was no significant difference in expression intensity between MIS/AMHRII protein and mRNA on all ovarian samples whether benign or malignant.
  • MIS/AMHRII protein and mRNA were weakly expressed on 45.45% of benign ovarian tumors.
  • Among malignant ovarian tumors, sex cord stromal tumors showed the highest expression rate and the strongest intensity of MIS/AMHRII protein and mRNA followed by germ cell tumor and epithelial ovarian tumor.
  • MIS/AMHRII and MIS/AMHRII mRNA demonstrate significantly variable expression among different ovarian tumor types.
  • Non-epithelial cell tumors show higher expression than those of epithelial cell tumors.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19424576.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptors, Peptide; 0 / Receptors, Transforming Growth Factor beta; 0 / anti-Mullerian hormone receptor; 80497-65-0 / Anti-Mullerian Hormone
  •  go-up   go-down


39. Behtash N, Karimi Zarchi M: Placental site trophoblastic tumor. J Cancer Res Clin Oncol; 2008 Jan;134(1):1-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Placental site trophoblastic tumor.
  • Placental site trophoblastic tumor (PSTT) is a rare neoplasm that rises from intermediate trophoblasts and commonly presents with low and variable concentration of HCG immunoactivity in serum, which can be difficult to differentiate from early stage choriocarcinoma/gestational trophoblastic neoplasm (GTN) or quiescent gestational trophoblastic disease.
  • There is a wide clinical spectrum of presentation and behavior ranging from a benign condition to an aggressive disease with fatal outcome.
  • Nontrophoblastic malignancies such as germ cell tumors or other tumors secreting low HCG must also be considered in the differential diagnosis.
  • [MeSH-major] Trophoblastic Tumor, Placental Site / pathology. Uterine Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2004 Feb;92(2):708-12 [14766272.001]
  • [Cites] Gynecol Oncol. 1999 May;73(2):216-22 [10329037.001]
  • [Cites] Cancer. 2002 Apr 15;94(8):2288-94 [12001129.001]
  • [Cites] Gynecol Oncol. 1988 Sep;31(1):32-42 [2842238.001]
  • [Cites] Gynecol Oncol. 2000 Jan;76(1):115-7 [10620452.001]
  • [Cites] Int J Gynecol Cancer. 2004 May-Jun;14 (3):558-63 [15228435.001]
  • [Cites] Hum Pathol. 1993 Oct;24(10):1098-106 [7691711.001]
  • [Cites] Med Pediatr Oncol. 2002 Mar;38(3):187-91; discussion 192 [11836719.001]
  • [Cites] Gynecol Oncol. 2001 Sep;82(3):415-9 [11520134.001]
  • [Cites] Clin Cancer Res. 1996 May;2(5):897-902 [9816247.001]
  • [Cites] Radiat Med. 1999 Nov-Dec;17 (6):427-30 [10646979.001]
  • [Cites] Obstet Gynecol Surv. 2003 Jul;58(7):484-8 [12832940.001]
  • [Cites] Hum Pathol. 1985 Jan;16(1):35-42 [2982714.001]
  • [Cites] Hum Pathol. 1998 Mar;29(3):280-8 [9496832.001]
  • [Cites] Lab Invest. 2000 Jun;80(6):965-72 [10879746.001]
  • [Cites] Gynecol Oncol. 1981 Oct;12(2 Pt 1):238-48 [6271654.001]
  • [Cites] World J Surg Oncol. 2005 Jun 15;3(1):34 [15958158.001]
  • [Cites] Gynecol Oncol. 1998 Jan;68(1):62-5 [9454662.001]
  • [Cites] J Reprod Med. 1998 Jan;43(1):37-43 [9475148.001]
  • [Cites] Histopathology. 1982 Mar;6(2):211-26 [6281156.001]
  • [Cites] Hum Pathol. 1998 Jan;29(1):27-33 [9445130.001]
  • [Cites] J Reprod Med. 2004 Jun;49(6):447-52 [15283052.001]
  • [Cites] APMIS Suppl. 1991;23:138-45 [1652995.001]
  • [Cites] Obstet Gynecol. 1985 Apr;65(4):527-34 [2984618.001]
  • [Cites] Hum Pathol. 1997 Nov;28(11):1302-6 [9385938.001]
  • [Cites] Placenta. 1984 Jul-Aug;5(4):349-69 [6209706.001]
  • [Cites] J Reprod Med. 2002 Jun;47(6):460-4 [12092014.001]
  • [Cites] Gynecol Oncol. 2006 Aug;102(2):160-4 [16631918.001]
  • [Cites] Hum Pathol. 1991 Sep;22(9):847-55 [1655617.001]
  • [Cites] Pathol Oncol Res. 2000;6(4):292-4 [11173663.001]
  • [Cites] Eur J Gynaecol Oncol. 2003;24(1):25-9 [12691312.001]
  • [Cites] Br J Cancer. 1992 Mar;65(3):355-8 [1348423.001]
  • [Cites] Cancer. 1976 Sep;38(3):1214-26 [182351.001]
  • [Cites] Gynecol Oncol. 2002 Dec;87(3):303-7 [12468329.001]
  • [Cites] Int J Gynecol Cancer. 1995 Jul;5(4):241-249 [11578484.001]
  • [Cites] Obstet Gynecol. 1985 Sep;66(3 Suppl):95S-100S [2991836.001]
  • [Cites] Acta Cytol. 1998 May-Jun;42(3):745-50 [9622699.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:445-8 [16515643.001]
  • [Cites] J Reprod Med. 1998 Jan;43(1):53-9 [9475150.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(4):854-9 [10673528.001]
  • [Cites] Int J Gynecol Cancer. 2004 Sep-Oct;14(5):980-3 [15361212.001]
  • (PMID = 17701427.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 48
  •  go-up   go-down


40. Wolff EF, Hughes M, Merino MJ, Reynolds JC, Davis JL, Cochran CS, Celi FS: Expression of benign and malignant thyroid tissue in ovarian teratomas and the importance of multimodal management as illustrated by a BRAF-positive follicular variant of papillary thyroid cancer. Thyroid; 2010 Sep;20(9):981-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of benign and malignant thyroid tissue in ovarian teratomas and the importance of multimodal management as illustrated by a BRAF-positive follicular variant of papillary thyroid cancer.
  • BACKGROUND: The most common type of ovarian germ cell tumor is the teratoma.
  • Thyroid tissue, both benign and malignant, may be a component of an ovarian teratoma.
  • SUMMARY: Malignant thyroid tissue is often difficult to distinguish from benign thyroid tissue arising in ovarian teratomas.
  • Postoperatively, tumor tissue should be referred to pathologists experienced with differentiating benign from malignant struma ovarii.
  • The tumor was found to be BRAF mutation positive (K601E).

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Thyroid cancer, follicular.
  • Genetic Alliance. consumer health - Thyroid cancer, papillary.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • Hazardous Substances Data Bank. LITHIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2009 Jun 18;360(25):2680-1; author reply 2682-3 [19537322.001]
  • [Cites] Endocr Pract. 2009 Mar;15(2):167-73 [19289330.001]
  • [Cites] Histopathology. 2009 Oct;55(4):482-7 [19817905.001]
  • [Cites] Endocr Pathol. 2010 Jun;21(2):144-7 [19898969.001]
  • [Cites] Gynecol Oncol. 2000 May;77(2):225-6 [10785468.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Aug;86(8):3512-5 [11502772.001]
  • [Cites] Gynecol Oncol. 2001 Sep;82(3):575-7 [11520159.001]
  • [Cites] Gynecol Oncol. 2002 Aug;86(2):231-4 [12144834.001]
  • [Cites] J Reprod Med. 2003 Jan;48(1):52-6 [12611097.001]
  • [Cites] Gynecol Oncol. 2004 Jul;94(1):226-8 [15262148.001]
  • [Cites] Clin Nucl Med. 1988 Dec;13(12):866-8 [3246114.001]
  • [Cites] J Clin Endocrinol Metab. 1989 Jul;69(1):186-90 [2499590.001]
  • [Cites] Int J Gynaecol Obstet. 1993 Aug;42(2):143-6 [7901063.001]
  • [Cites] Int J Gynecol Pathol. 1993 Oct;12(4):333-43 [8253550.001]
  • [Cites] Pathol Res Pract. 1994 Nov;190(11):1082-5; discussion 1086-8 [7746743.001]
  • [Cites] Histopathology. 1997 Sep;31(3):289-90 [9354902.001]
  • [Cites] J Postgrad Med. 1996 Apr-Jun;42(2):39-42 [9715297.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Mar;84(3):912-6 [10084570.001]
  • [Cites] Gynecol Oncol. 2005 Apr;97(1):282-4 [15790478.001]
  • [Cites] Curr Opin Obstet Gynecol. 2005 Jun;17(3):299-308 [15870565.001]
  • [Cites] Hum Pathol. 2005 Jun;36(6):694-7 [16021577.001]
  • [Cites] Int J Gynecol Cancer. 2005 Nov-Dec;15(6):1156-9 [16343201.001]
  • [Cites] Thyroid. 2005 Dec;15(12):1355-61 [16405408.001]
  • [Cites] Pathology. 2007 Feb;39(1):139-46 [17365830.001]
  • [Cites] Gynecol Oncol. 2007 May;105(2):321-4 [17240432.001]
  • [Cites] Int J Surg Pathol. 2007 Apr;15(2):116-20 [17478764.001]
  • [Cites] Am J Surg Pathol. 2007 Sep;31(9):1337-43 [17721188.001]
  • [Cites] Endocr Pathol. 2007 Fall;18(3):182-6 [18058267.001]
  • [Cites] Clin Nucl Med. 2008 Apr;33(4):247-50 [18356660.001]
  • [Cites] Int J Gynecol Pathol. 2008 Apr;27(2):213-22 [18317221.001]
  • [Cites] Gynecol Endocrinol. 2008 Jun;24(6):312-9 [18584410.001]
  • [Cites] Ultrasound Obstet Gynecol. 2008 Aug;32(2):210-9 [18636616.001]
  • [Cites] Ceylon Med J. 2008 Jun;53(2):55-6 [18678124.001]
  • [Cites] Int J Gynecol Pathol. 2008 Oct;27(4):496-506 [18753973.001]
  • [Cites] Obstet Gynecol Surv. 2008 Nov;63(11):725-32 [18928577.001]
  • [Cites] Cancer Genet Cytogenet. 2009 Apr 1;190(1):15-20 [19264228.001]
  • [Cites] Thyroid. 2009 Oct;19(10):1093-8 [19732012.001]
  • (PMID = 20718682.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Intramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Isotopes; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 9010-34-8 / Thyroglobulin; 9FN79X2M3F / Lithium; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; Q51BO43MG4 / Thyroxine
  • [Other-IDs] NLM/ PMC2964358
  •  go-up   go-down


41. Gorosito M, Pancera B, Sarancone S, Nocito AL: Gonadoblastoma: an unusual ovarian tumor. Ann Diagn Pathol; 2010 Aug;14(4):247-50
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gonadoblastoma: an unusual ovarian tumor.
  • Gonadoblastomas are unusual benign neoplasias that frequently appear in the dysgenetic gonads of women with chromosome Y anomaly.
  • In all the cases, the histologic examination showed germ cell proliferation and sex cords derivatives frequently surrounding small round deposits containing amorphous hyaline material resembling Call-Exner bodies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20637428.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Sajadi KP, Dalton RR, Brown JA: Sex cord-gonadal stromal tumor of the rete testis. Adv Urol; 2009;:624173

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sex cord-gonadal stromal tumor of the rete testis.
  • The radical orchiectomy specimen contained an undifferentiated spindled sex cord-stromal tumor arising in the rete testis.
  • Testicular sex cord-stromal tumors are far less common than germ cell neoplasms and are usually benign.
  • This undifferentiated sex cord-stromal tumor, occurring in a previously unreported location, is an example of an unusual lesion mimicking an intratesticular malignant neoplasm.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Diagn Pathol. 2000 Nov;17(4):258-69 [11202544.001]
  • [Cites] Radiographics. 2002 Jan-Feb;22(1):189-216 [11796908.001]
  • [Cites] Semin Diagn Pathol. 2000 Nov;17(4):270-93 [11202545.001]
  • [Cites] Virchows Arch. 2004 Jun;444(6):567-71 [15088145.001]
  • [Cites] Mod Pathol. 1997 Jul;10(7):693-700 [9237180.001]
  • [Cites] Pathol Annu. 1990;25 Pt 2:51-108 [2202966.001]
  • [Cites] Mod Pathol. 2005 Feb;18 Suppl 2:S131-45 [15502808.001]
  • (PMID = 19125206.001).
  • [ISSN] 1687-6369
  • [Journal-full-title] Advances in urology
  • [ISO-abbreviation] Adv Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2612754
  •  go-up   go-down


43. Gwin K, Mariño-Enríquez A, Martel M, Reyes-Múgica M: Sclerosing stromal tumor: an important differential diagnosis of ovarian neoplasms in childhood and adolescence. Pediatr Dev Pathol; 2009 Sep-Oct;12(5):366-70
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sclerosing stromal tumor: an important differential diagnosis of ovarian neoplasms in childhood and adolescence.
  • Sclerosing stromal tumors are an uncommon type of benign ovarian sex cord-stromal tumor.
  • Although the usual age of presentation is in the 2nd and 3rd decades, sclerosing stromal tumor can occur in adolescence or premenarchal girls.
  • Imaging studies frequently reveal solid or complex cystic adnexal masses with marked vascularity raising concern for germ cell tumors and, especially in the absence of elevated tumor markers, surface epithelial neoplasms.
  • The differential diagnosis of a benign sclerosing stromal tumor is seldom entertained.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19071970.001).
  • [ISSN] 1093-5266
  • [Journal-full-title] Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • [ISO-abbreviation] Pediatr. Dev. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Venizelos ID, Tatsiou ZA, Roussos D, Karagiannis V: A case of sebaceous carcinoma arising within a benign ovarian cystic teratoma. Onkologie; 2009 Jun;32(6):353-5
MedlinePlus Health Information. consumer health - Ovarian Cysts.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of sebaceous carcinoma arising within a benign ovarian cystic teratoma.
  • BACKGROUND: Mature cystic teratoma, also known as dermoid cyst, is the most common germ cell tumor of the ovary.
  • Malignant change in a component of a mature ovarian teratoma is rare, occurring in less than 2% of cases, with squamous cell carcinoma corresponding to 80% of such neoplasms.
  • Abdominal and pelvic ultrasound as well as computed tomography demonstrated a heterogenic tumor of the right ovary.
  • Histological examination of the tumor showed features of a well-differentiated sebaceous carcinoma arising within a mature cystic teratoma.

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19521124.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


45. Denayer E, Devriendt K, de Ravel T, Van Buggenhout G, Smeets E, Francois I, Sznajer Y, Craen M, Leventopoulos G, Mutesa L, Vandecasseye W, Massa G, Kayserili H, Sciot R, Fryns JP, Legius E: Tumor spectrum in children with Noonan syndrome and SOS1 or RAF1 mutations. Genes Chromosomes Cancer; 2010 Mar;49(3):242-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor spectrum in children with Noonan syndrome and SOS1 or RAF1 mutations.
  • One was classified as a rare benign variant and the other remains unclassified.
  • Three patients with SOS1 mutations presented with tumors (embryonal rhabdomyosarcoma, Sertoli cell testis tumor, and granular cell tumors of the skin).
  • One patient with a RAF1 mutation had a lesion suggestive for a giant cell tumor.
  • This is the first report describing different tumor types in NS patients with germ line SOS1 mutations.


46. Thomas L, Kluwe L, Chuzhanova N, Mautner V, Upadhyaya M: Analysis of NF1 somatic mutations in cutaneous neurofibromas from patients with high tumor burden. Neurogenetics; 2010 Oct;11(4):391-400
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of NF1 somatic mutations in cutaneous neurofibromas from patients with high tumor burden.
  • Neurofibromatosis type 1, (NF1) is a complex, autosomal dominant disorder characterized by benign and malignant tumors which result from NF1 gene mutations.
  • These modifying loci may include deficiencies in mismatch repair genes and elements involved in cell cycle regulation (TP53, RB1, and CDKN2A).
  • We have analyzed the somatic mutations in 89 cutaneous neurofibromas derived from three unrelated NF1 patients with high tumor burden, by loss of heterozygosity (LOH) analysis of the NF1, TP53, RB1, and CDKN2A genes, by assessing microsatellite instability (MSI), by direct sequencing of the NF1, TP53, and several mismatch repair (MMR) genes and by multiplex ligation-dependent probe amplification of the NF1 and TP53 genes.
  • Each mutation was distinct demonstrating the independent origin of each tumor.
  • LOH of markers flanking the RB1 gene was also found in one tumor but no CDKN2A mutations were detected.
  • The identification of LOH involving TP53 and RB1 loci is a novel finding in benign cutaneous neurofibromas possibly demonstrating an alternative underlying molecular mechanism associated with the development of these benign tumors from this cohort of patients.
  • [MeSH-minor] Adult. Computational Biology / methods. Cyclin-Dependent Kinase Inhibitor p16 / genetics. DNA Mutational Analysis. Female. Genes, p53. Germ-Line Mutation. Humans. Loss of Heterozygosity. Male. Middle Aged. Retinoblastoma Protein / genetics

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1998 May 21;393(6682):229-34 [9607760.001]
  • [Cites] Hum Genet. 2008 Sep;124(2):105-22 [18709565.001]
  • [Cites] Electrophoresis. 2008 Dec;29(23):4627-36 [19053154.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):1879-84 [10595918.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Oct;45(10):893-904 [16830335.001]
  • [Cites] Hum Genet. 2003 Feb;112(2):117-23 [12522551.001]
  • [Cites] Hum Mutat. 2004 Feb;23(2):177-85 [14722921.001]
  • [Cites] Clin Cancer Res. 2008 Feb 15;14(4):1015-24 [18281533.001]
  • [Cites] Cell Stem Cell. 2009 May 8;4(5):453-63 [19427294.001]
  • [Cites] Cancer Res. 2005 Oct 1;65(19):8662-70 [16204034.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):1154-61 [11221846.001]
  • [Cites] Virchows Arch. 2002 Jun;440(6):610-5 [12070601.001]
  • [Cites] Nat Genet. 2001 Jul;28(3):294-6 [11431704.001]
  • [Cites] Hum Mutat. 2004 Feb;23(2):134-46 [14722917.001]
  • [Cites] Hum Mutat. 2006 Oct;27(10 ):1030-40 [16941471.001]
  • [Cites] Cancer Res. 1995 Dec 1;55(23):5677-80 [7585653.001]
  • [Cites] Trends Cell Biol. 2009 Aug;19(8):395-403 [19615906.001]
  • [Cites] Am J Hum Genet. 1997 Sep;61(3):512-9 [9326316.001]
  • [Cites] J Med Genet. 2007 Feb;44(2):81-8 [17105749.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Mar;157(2):181-6 [15721644.001]
  • [Cites] Am J Med Genet A. 2008 Jun 1;146A(11):1444-52 [18438896.001]
  • [Cites] Nucleic Acids Res. 1991 Dec 25;19(24):6977 [1762941.001]
  • [Cites] J Vis Exp. 2007;(8):309 [18989416.001]
  • [Cites] Nat Genet. 1995 Oct;11(2):210-2 [7550353.001]
  • [Cites] Nucleic Acids Res. 1991 Sep 11;19(17):4796 [1716362.001]
  • [Cites] Biochem Biophys Res Commun. 1997 May 19;234(2):346-50 [9177273.001]
  • [Cites] Curr Opin Neurol. 2004 Apr;17(2):101-5 [15021234.001]
  • [Cites] Hum Mutat. 2005 Sep;26(3):205-13 [16086312.001]
  • [Cites] Biochim Biophys Acta. 2000 Jul 31;1471(1):M13-9 [10967421.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Aug;10(4):250-5 [7522538.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Sep;46(9):820-7 [17563086.001]
  • [Cites] Science. 1999 Dec 10;286(5447):2172-6 [10591652.001]
  • [Cites] Hum Mutat. 2003 Sep;22(3):229-44 [12938088.001]
  • [Cites] Hum Mutat. 2008 Aug;29(8):E103-11 [18484666.001]
  • [Cites] Cell. 2001 Feb 23;104(4):593-604 [11239415.001]
  • [Cites] Am J Hum Genet. 1989 Oct;45(4):547-55 [2577468.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14162-7 [15377784.001]
  • [Cites] Hum Genet. 2000 Jul;107(1):33-9 [10982032.001]
  • [Cites] Fam Cancer. 2007;6(4):463-71 [17551851.001]
  • [Cites] J Med Genet. 2000 Jan;37(1):44-9 [10633134.001]
  • [Cites] Science. 1999 Dec 10;286(5447):2176-9 [10591653.001]
  • [Cites] Mol Cell Probes. 1999 Apr;13(2):157-65 [10208807.001]
  • [Cites] Lab Invest. 2000 May;80(5):709-18 [10830781.001]
  • [Cites] Glia. 2008 Nov 1;56(14):1590-605 [18803326.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):1855-60 [10595915.001]
  • [Cites] Bioinformatics. 1999 Dec;15(12):994-9 [10745989.001]
  • [Cites] Eur J Hum Genet. 2000 Dec;8(12):939-45 [11175282.001]
  • [Cites] Cancer Res. 1996 Aug 15;56(16):3842-9 [8706033.001]
  • [Cites] Cancer Res. 2008 Jul 1;68(13):5059-66 [18593904.001]
  • [Cites] Neurosurgery. 2006 Jan;58(1):1-16; discussion 1-16 [16385324.001]
  • [Cites] Diagn Mol Pathol. 1996 Sep;5(3):214-9 [8866236.001]
  • [Cites] Hum Mutat. 2003 Jan;21(1):28-44 [12497629.001]
  • (PMID = 20358387.001).
  • [ISSN] 1364-6753
  • [Journal-full-title] Neurogenetics
  • [ISO-abbreviation] Neurogenetics
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Retinoblastoma Protein
  •  go-up   go-down


47. Mhawech-Fauceglia P, Herrmann FR, Bshara W, Odunsi K, Terracciano L, Sauter G, Cheney RT, Groth J, Penetrante R, Mhawech-Fauceglia P: Friend leukaemia integration-1 expression in malignant and benign tumours: a multiple tumour tissue microarray analysis using polyclonal antibody. J Clin Pathol; 2007 Jun;60(6):694-700

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Friend leukaemia integration-1 expression in malignant and benign tumours: a multiple tumour tissue microarray analysis using polyclonal antibody.
  • However, it is also expressed in subsets of lymphoblastic lymphoma, Merkel cell carcinoma (MCC) and desmoplastic small round cell tumour (DSRCT).
  • AIM: To determine expression of FLI-1 in various benign and malignant neoplasms, by immunohistochemical analysis on 4323 tumours using multiple tumour microarrays, as well as on whole sections.
  • RESULTS: FLI-1 was expressed in 46/62 EWS/PNETs, 2/3 olfactory neuroblastomas, 7/102 small cell carcinomas of the lung, 10/34 MCCs, 1/14 rhabdomyosarcoma, 19/132 non-Hodgkin's lymphomas, 2/3 DSRCTs, and in 53/74 benign and malignant vascular tumours.
  • In addition, 27/508 squamous cell carcinomas, 19/837 adenocarcinomas, 10/400 urothelial bladder cancers, 1/40 basal cell carcinomas, 3/29 liposarcomas, 1/40 glioblastoma multiforme and 9/29 medullar carcinomas of the breast expressed FLI-1.
  • Finally, the sensitivity and specificity of FLI-1 to distinguish EWS/PNET from other small round cell tumours (SRCTs) were 74.2% and 91.6%, respectively.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Neoplasms / metabolism. Proto-Oncogene Protein c-fli-1 / metabolism
  • [MeSH-minor] Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / metabolism. Diagnosis, Differential. Humans. Immunoenzyme Techniques. Neoplasms, Germ Cell and Embryonal / diagnosis. Neoplasms, Germ Cell and Embryonal / metabolism. Neuroectodermal Tumors, Primitive / diagnosis. Neuroectodermal Tumors, Primitive / metabolism. Protein Array Analysis / methods. Sarcoma, Ewing / diagnosis. Sarcoma, Ewing / metabolism. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1061-6 [11474291.001]
  • [Cites] Am J Surg Pathol. 2000 Dec;24(12):1657-62 [11117787.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5747-54 [11607824.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):320-7 [11859203.001]
  • [Cites] Hum Pathol. 2003 Oct;34(10):994-1000 [14608532.001]
  • [Cites] Hum Pathol. 2004 Jan;35(1):122-8 [14745734.001]
  • [Cites] Mod Pathol. 2004 May;17(5):547-52 [15001993.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2004 Jun;12(2):160-5 [15354743.001]
  • [Cites] Am J Clin Pathol. 2004 Nov;122(5):721-7 [15491968.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Int J Dev Biol. 1998 May;42(4):561-72 [9694627.001]
  • [Cites] Histopathology. 2005 Jun;46(6):622-34 [15910593.001]
  • [Cites] Am J Surg Pathol. 2005 Aug;29(8):1025-33 [16006796.001]
  • [Cites] Am J Surg Pathol. 2005 Sep;29(9):1184-93 [16096408.001]
  • [Cites] Int J Gynecol Pathol. 2006 Apr;25(2):151-4 [16633064.001]
  • [Cites] Semin Diagn Pathol. 2000 Aug;17(3):216-24 [10968707.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2001 Sep;9(3):255-60 [11556754.001]
  • (PMID = 16917000.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Protein c-fli-1
  • [Other-IDs] NLM/ PMC1955051
  •  go-up   go-down


48. Liberis V, Tsikouras P, Sivridis E, Dadidou M, Koutlaki N, Galazios G: Irregular dental structures in a benign ovarian cystic teratoma (dermoid cyst): case report. Clin Exp Obstet Gynecol; 2008;35(2):151-2
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Irregular dental structures in a benign ovarian cystic teratoma (dermoid cyst): case report.
  • Mature cystic teratomas, often referred to as dermoid cysts, are the most common germ cell tumors of the ovary in women of reproductive age.
  • We present a case of a dermoid cyst ovarian tumor in a 24-your-old patient with a tooth lying on each wall.

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18581775.001).
  • [ISSN] 0390-6663
  • [Journal-full-title] Clinical and experimental obstetrics & gynecology
  • [ISO-abbreviation] Clin Exp Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


49. Merchant A, Stewart RW: Sacrococcygeal yolk sac tumor presenting as subcutaneous fluid collection initially treated as abscess. South Med J; 2010 Oct;103(10):1068-70
MedlinePlus Health Information. consumer health - Abscess.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sacrococcygeal yolk sac tumor presenting as subcutaneous fluid collection initially treated as abscess.
  • Malignant extragonadal germ cell tumors, though more common in infants and children, are rare.
  • We report a case of an 11-month-old female with sacrococcygeal extragonadal yolk sac tumor manifesting as a draining subcutaneous nodule after initial treatment as an abscess.
  • Extragonadal germ cell tumors can present with external manifestations confusingly similar to other more benign soft tissue conditions.
  • [MeSH-major] Abscess / diagnosis. Endodermal Sinus Tumor / diagnosis. Sacrococcygeal Region

  • Genetic Alliance. consumer health - Yolk sac tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20818302.001).
  • [ISSN] 1541-8243
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Dong Z, Yang Z, Li Y, Min P, Zhang X: [Extra-organic primary tumor in pelvis: correlation of multi-detector row computed tomography, anatomy and pathology]. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2009 Feb;26(1):75-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Extra-organic primary tumor in pelvis: correlation of multi-detector row computed tomography, anatomy and pathology].
  • The majority of entities in these 2 pouches were germ cell tumors (3/5 cases, 60.0%).
  • The majority entities of these 10 cases were germ cell tumors (7/10 cases, 70.0%).
  • The fatty element occurred in 7 masses, including 4 cases of teratoma, 1 case of malignant teratoma, 1 case of mixed germ cell tumor, and 1 case of liposarcoma.
  • MDCT with multi-planar reconstruction (MPR) could more clearly reveal the anatomic location of the extra-organic primary tumor in pelvis, could unveil the tumor's relationship with its surrounding organs, and could help to differentiate benign tumors from malignant tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19334559.001).
  • [ISSN] 1001-5515
  • [Journal-full-title] Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi
  • [ISO-abbreviation] Sheng Wu Yi Xue Gong Cheng Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


51. Kozlov AP: The possible evolutionary role of tumors in the origin of new cell types. Med Hypotheses; 2010 Jan;74(1):177-85

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The possible evolutionary role of tumors in the origin of new cell types.
  • The ability of tumor cells to differentiate in combination with their ability to express genes that are not expressed in normal tissues, may result in the emergence of new cell types in evolution.
  • Genetically or epigenetically predetermined tumors at the early stages of progression, benign tumors, and some tumor-like processes in invertebrates and plants, all of which are modes of excess cell growth which provide evolving multicellular organisms with extra cell masses, are considered as potentially evolutionarily meaningful.
  • The preexisting cell types of multicellular organisms had restricted potential for the expression of newly evolving genes.
  • Multicellular organisms would need excess cell masses for the expression of newly evolving genes.
  • The preexisting cell types cannot provide such excess cell masses because of limitations imposed on the number of possible cell divisions.
  • Tumors could provide the evolving multicellular organisms with the excess cell masses for the expression of newly evolving genes.
  • We suggest that tumors could be a sort of proving ground (or reservoir) for the expression of newly evolving genes that originate in the course of genome evolution in the DNA of germ cells (i.e., not in tumor cells themselves).
  • Tumor cells would differentiate, resulting in a new cell type for the given multicellular species.
  • This cell type would be inherited because of epigenomic mechanisms similar to those in preexisting cell types.
  • Populations of tumor-bearing organisms with genetically or epigenetically programmed tumors could represent the transition between established species of organisms at different stages of progressive evolution.
  • Experimental confirmation of the prediction of the hypothesis of evolution by tumor cells differentiation concerning the expression of evolutionarily new genes and/or silent (neutrally evolving) sequences in tumor cells is presented.
  • [MeSH-minor] Animals. Biological Evolution. Cell Differentiation. Cell Line, Tumor. Humans. Mice. Models, Biological. Models, Genetic. Rhizobium / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19665850.001).
  • [ISSN] 1532-2777
  • [Journal-full-title] Medical hypotheses
  • [ISO-abbreviation] Med. Hypotheses
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Spurlock G, Knight SJ, Thomas N, Kiehl TR, Guha A, Upadhyaya M: Molecular evolution of a neurofibroma to malignant peripheral nerve sheath tumor (MPNST) in an NF1 patient: correlation between histopathological, clinical and molecular findings. J Cancer Res Clin Oncol; 2010 Dec;136(12):1869-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular evolution of a neurofibroma to malignant peripheral nerve sheath tumor (MPNST) in an NF1 patient: correlation between histopathological, clinical and molecular findings.
  • OBJECTIVE: Neurofibromatosis type 1 (NF1) patients have a 13% risk of developing a malignant peripheral nerve sheath tumor (MPNST).
  • Many MPNSTs are histopathologically complex, with regions exhibiting features of the original benign plexiform neurofibroma (PNF), of an atypical PNF, or of MPNST showing varying degrees of de-differentiation.
  • This study analyzed the genetic alterations associated with this pathological heterogeneity in order to identify the genetic processes involved in transformation from a benign to an aggressive malignant tumor.
  • METHODS: A histological and molecular analysis of a single MPNST tumor that was subdivided into three histopathologically distinct regions, a benign PNF (region 1), an atypical PNF (region 2), and a high-grade MPNST (region 3), was carried out.
  • Tumor DNA from each region was analyzed in conjunction with the patient's lymphocyte DNA.
  • The NF1-associated LOH analysis found that LOH increased in the three tumor areas, with 9, 42, and 97% LOH evident in regions 1, 2, and 3, respectively.
  • Additional genetic changes, including losses of TP53, RB1, CDKN2A, and of several oncogenes and cell-cycle genes, were found only in the malignant MPNST (region 3).
  • [MeSH-minor] Adult. Base Sequence. Comparative Genomic Hybridization. DNA Mutational Analysis. Disease Progression. Germ-Line Mutation. Humans. Loss of Heterozygosity. Male. Molecular Sequence Data

  • Genetic Alliance. consumer health - Neurofibroma.
  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Hum Genet. 2006 Jul;79(1):143-8 [16773574.001]
  • [Cites] J Exp Med. 1994 Jul 1;180(1):35-42 [8006593.001]
  • [Cites] Genes Chromosomes Cancer. 2009 Oct;48(10):897-907 [19603524.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Feb;30(2):202-6 [11135438.001]
  • [Cites] Anticancer Res. 2009 Apr;29(4):1255-62 [19414372.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Oct;45(10):893-904 [16830335.001]
  • [Cites] Hum Mutat. 2008 Jan;29(1):74-82 [17960768.001]
  • [Cites] Clin Cancer Res. 2008 Feb 15;14(4):1015-24 [18281533.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Sep;32(1):89-94 [11477665.001]
  • [Cites] J Med Genet. 2002 May;39(5):311-4 [12011145.001]
  • [Cites] Neurosurgery. 1998 Jul;43(1):56-64; discussion 64-5 [9657189.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):295-308 [17384584.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3515-9 [8170938.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):398-407 [17202312.001]
  • [Cites] Neurology. 2005 Jul 26;65(2):205-11 [16043787.001]
  • [Cites] Hum Mutat. 2004 Feb;23(2):134-46 [14722917.001]
  • [Cites] Fam Cancer. 2007;6(1):147-52 [16944271.001]
  • [Cites] Am J Pathol. 1985 Jan;118(1):85-95 [3881039.001]
  • [Cites] Am J Med Genet A. 2008 Jun 1;146A(11):1444-52 [18438896.001]
  • [Cites] Arch Pathol Lab Med. 2006 Dec;130(12):1878-81 [17149968.001]
  • [Cites] Nucleic Acids Res. 1991 Dec 25;19(24):6977 [1762941.001]
  • [Cites] N Engl J Med. 1997 Jun 12;336(24):1713-20 [9180088.001]
  • [Cites] Nat Genet. 1995 Oct;11(2):210-2 [7550353.001]
  • [Cites] Lancet Oncol. 2009 May;10(5):508-15 [19410195.001]
  • [Cites] Hum Mol Genet. 2006 Mar 15;15(6):1015-23 [16461335.001]
  • [Cites] J Clin Pathol. 2004 Nov;57(11):1172-8 [15509679.001]
  • [Cites] Mod Pathol. 2000 Sep;13(9):988-93 [11007039.001]
  • [Cites] Br J Cancer. 2004 Mar 8;90(5):1041-6 [14997205.001]
  • [Cites] Endocr Relat Cancer. 2004 Dec;11(4):815-22 [15613454.001]
  • [Cites] Mol Cancer. 2008 Jun 03;7:48 [18522746.001]
  • [Cites] EMBO Mol Med. 2009 Jul;1(4):236-48 [20049725.001]
  • [Cites] J Pathol. 2006 Aug;209(4):492-500 [16721726.001]
  • [Cites] Hum Mutat. 2008 Aug;29(8):E103-11 [18484666.001]
  • [Cites] Cell. 2001 Feb 23;104(4):593-604 [11239415.001]
  • [Cites] Am J Pathol. 1986 May;123(2):195-203 [3518473.001]
  • [Cites] Mol Cancer. 2004 Jul 15;3:20 [15255999.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Jul;92(7):2784-92 [17426081.001]
  • [Cites] Cancer Res. 2009 Sep 15;69(18):7393-401 [19738042.001]
  • [Cites] J Neuropathol Exp Neurol. 1995 Jan;54(1):65-73 [7815081.001]
  • [Cites] FEBS Lett. 2006 Jun 12;580(14 ):3395-400 [16723126.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4778-81 [8840998.001]
  • [Cites] Hum Mol Genet. 2000 Dec 12;9(20):3055-64 [11115850.001]
  • [Cites] Lab Invest. 2000 May;80(5):709-18 [10830781.001]
  • [Cites] Glia. 2008 Nov 1;56(14):1590-605 [18803326.001]
  • [Cites] Cancer Cell. 2009 Jan 6;15(1):45-56 [19111880.001]
  • [Cites] Oncogene. 1996 Feb 1;12(3):507-13 [8637706.001]
  • [Cites] Annu Rev Med. 2007;58:267-84 [17002552.001]
  • [Cites] Diagn Mol Pathol. 1996 Sep;5(3):214-9 [8866236.001]
  • (PMID = 20229272.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / / 075491/Z/04; United Kingdom / Cancer Research UK / /
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Neurofibromin 1
  •  go-up   go-down


53. Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brünner N, Chan DW, Babaian R, Bast RC Jr, Dowell B, Esteva FJ, Haglund C, Harbeck N, Hayes DF, Holten-Andersen M, Klee GG, Lamerz R, Looijenga LH, Molina R, Nielsen HJ, Rittenhouse H, Semjonow A, Shih IeM, Sibley P, Sölétormos G, Stephan C, Sokoll L, Hoffman BR, Diamandis EP, National Academy of Clinical Biochemistry: National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem; 2008 Dec;54(12):e11-79
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.
  • BACKGROUND: Updated National Academy of Clinical Biochemistry (NACB) Laboratory Medicine Practice Guidelines for the use of tumor markers in the clinic have been developed.
  • METHODS: Published reports relevant to use of tumor markers for 5 cancer sites--testicular, prostate, colorectal, breast, and ovarian--were critically reviewed.
  • RESULTS: For testicular cancer, alpha-fetoprotein, human chorionic gonadotropin, and lactate dehydrogenase are recommended for diagnosis/case finding, staging, prognosis determination, recurrence detection, and therapy monitoring. alpha-Fetoprotein is also recommended for differential diagnosis of nonseminomatous and seminomatous germ cell tumors.
  • Free PSA measurement data are useful for distinguishing malignant from benign prostatic disease when total PSA is <10 microg/L.
  • CONCLUSIONS: Implementation of these recommendations should encourage optimal use of tumor markers.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / diagnosis. Clinical Laboratory Techniques. Colorectal Neoplasms / diagnosis. Ovarian Neoplasms / diagnosis. Prostatic Neoplasms / diagnosis. Testicular Neoplasms / diagnosis


54. Kim E, Bae TS, Kwon Y, Kim TH, Chung KW, Kim SW, Ro J, Lee ES: Primary malignant teratoma with a primitive neuroectodermal tumor component in thyroid gland: a case report. J Korean Med Sci; 2007 Jun;22(3):568-71
Genetic Alliance. consumer health - Teratoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant teratoma with a primitive neuroectodermal tumor component in thyroid gland: a case report.
  • Teratomas comprise the most common extragonadal germ cell tumors in childhood.
  • Most teratomas involving the thyroid are benign and occur in children.
  • This is the first case, to our knowledge, of malignant thyroid teratoma with a exuberant primitive neuroectodermal tumor component in Korea.
  • [MeSH-minor] Adult. Female. Head and Neck Neoplasms / pathology. Humans. Neoplasm Metastasis. Positron-Emission Tomography / methods. Thyroid Diseases / diagnosis. Thyroidectomy. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Mar 1;88(5):1149-58 [10699906.001]
  • [Cites] Am J Otolaryngol. 2000 Mar-Apr;21(2):112-5 [10758996.001]
  • [Cites] Acta Cytol. 2000 May-Jun;44(3):375-9 [10833994.001]
  • [Cites] Ann Diagn Pathol. 2001 Oct;5(5):285-92 [11598856.001]
  • [Cites] N Engl J Med. 2003 Feb 20;348(8):694-701 [12594313.001]
  • [Cites] Thyroid. 2003 Apr;13(4):401-4 [12804109.001]
  • [Cites] Ann Oncol. 1998 Sep;9(9):1015-22 [9818077.001]
  • [Cites] J Clin Oncol. 1995 Nov;13(11):2796-804 [7595741.001]
  • [Cites] Am J Surg Pathol. 1997 Aug;21(8):896-904 [9255252.001]
  • [Cites] Am J Clin Oncol. 1998 Apr;21(2):212-4 [9537215.001]
  • [Cites] Ann Hematol. 1998 May;76(5):183-8 [9671130.001]
  • [Cites] Head Neck. 1998 Oct;20(7):649-53 [9744468.001]
  • [Cites] Bull Cancer. 1995;82 Suppl 1:56s-60s [7542945.001]
  • (PMID = 17596674.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2693658
  •  go-up   go-down


55. Kumamoto H, Ooya K: Immunohistochemical detection of platelet-derived endothelial cell growth factor/thymidine phosphorylase and angiopoietins in ameloblastic tumors. J Oral Pathol Med; 2006 Nov;35(10):606-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical detection of platelet-derived endothelial cell growth factor/thymidine phosphorylase and angiopoietins in ameloblastic tumors.
  • BACKGROUND: To evaluate the roles of angiogenic factors in the development and progression of odontogenic tumors, expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase (PD-ECGF/TP) and of angiopoietins in ameloblastic tumors as well as in tooth germs.
  • Granular cell ameloblastomas showed PD-ECGF/TP reactivity in granular neoplastic cells as well as in stromal cells.
  • Immunoreactivity for angiopoietin-1 and -2 was detected predominantly in odontogenic epithelial cells near the basement membrane in tooth germs and in benign and malignant ameloblastic tumors.
  • CONCLUSION: Expression of PD-ECGF/TP and angiopoietin-1 and -2 in tooth germs and ameloblastic tumors suggests that these angiogenic factors participate in tooth development and odontogenic tumor progression by regulating angiogenesis.
  • Altered expression of PD-ECGF/TP and angiopoietins in ameloblastic tumors may be involved in oncogenesis, malignant potential, and tumor cell differentiation.
  • [MeSH-minor] Humans. Stromal Cells / chemistry. Stromal Cells / enzymology. Tooth Germ / chemistry. Tooth Germ / enzymology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17032393.001).
  • [ISSN] 0904-2512
  • [Journal-full-title] Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • [ISO-abbreviation] J. Oral Pathol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / ANGPT1 protein, human; 0 / Angiopoietin-1; 0 / Angiopoietin-2; EC 2.4.2.4 / Thymidine Phosphorylase
  •  go-up   go-down


61. Fujimura T, Takahashi S, Urano T, Xiaoqiang L, Ogushi T, Muramatsu M, Ouchi Y, Kitamura T, Homma Y, Inoue S: Estrogen receptor-binding fragment-associated gene 9 expression and its clinical significance in human testicular cancer. Int J Urol; 2009 Mar;16(3):329-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: We previously demonstrated that estrogen receptor-binding fragment-associated gene 9 (EBAG9) is a tumor promoting factor in renal cell carcinoma (Ogushi T, Cancer Res.
  • METHODS: We investigated the expression of EBAG9 in 90 testicular specimens (28 benign testicular tissue and 62 testicular germ cell tumor samples) by immunohistochemistry using rabbit polyclonal anti-EBAG9 antibody.
  • RESULTS: Positive immunostaining of EBAG9 in the cytoplasm was found in 32 (52%) cancerous lesions, whereas the immunoreactivity of EBAG9 was weak in benign testicular tissues.
  • The EBAG9-positive cases among the patients with advanced clinical stage (Stage II and III) more frequently belonged to the intermediate or poor risk group in the International Germ Cell Consensus Prognostic Classification System (IGCCPCS), compared with the EBAG9-negative cases (P = 0.0012).
  • CONCLUSIONS: These findings suggest that increased expression of EBAG9 may play a significant role in cancer progression and aggressiveness in testicular germ cell tumors.
  • [MeSH-major] Antigens, Neoplasm / genetics. Gene Expression Regulation, Neoplastic. Neoplasms, Germ Cell and Embryonal / genetics. Testicular Neoplasms / genetics
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Biomarkers, Tumor / genetics. Cohort Studies. Frozen Sections. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Orchiectomy / methods. Probability. Prognosis. Retrospective Studies. Risk Assessment. Sensitivity and Specificity. Statistics, Nonparametric. Survival Analysis. Young Adult

  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19207611.001).
  • [ISSN] 1442-2042
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / EBAG9 protein, human
  •  go-up   go-down


62. Wilson C, Idziaszczyk S, Parry L, Guy C, Griffiths DF, Lazda E, Bayne RA, Smith AJ, Sampson JR, Cheadle JP: A mouse model of tuberous sclerosis 1 showing background specific early post-natal mortality and metastatic renal cell carcinoma. Hum Mol Genet; 2005 Jul 1;14(13):1839-50
SciCrunch. Marmoset Gene list: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A mouse model of tuberous sclerosis 1 showing background specific early post-natal mortality and metastatic renal cell carcinoma.
  • Tuberous sclerosis complex (TSC) is an autosomal dominant disorder caused by mutations in either the TSC1 or the TSC2 genes and characterized by the development of benign hamartomatous growths in multiple organ systems.
  • We have inactivated Tsc1 in the mouse germ line by gene targeting in ES cells and confirmed that the mutant allele (Tsc1-) has a recessive embryonic lethal phenotype.
  • Eighty percent (16/20) of Tsc1+/- mice on a Balb/c background exhibited solid renal cell carcinomas (RCC) by 15-18 months and in 41%, RCCs were > or = 5 mm, resulting in grossly deformed kidneys.
  • [MeSH-major] Carcinoma, Renal Cell / genetics. Kidney Neoplasms / genetics. Tuberous Sclerosis / genetics. Tumor Suppressor Proteins / genetics


63. Stremmel C, Passlick B: [Surgery of mediastinal tumors]. Chirurg; 2008 Jan;79(1):9-10, 12-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thymomas, lymphomas, and germ cell tumors are the most frequent lesions of the anterior mediastinum, whereas endodermal (bronchogenic) cysts and lymphomas are the most frequent lesions of the middle mediastinum.
  • Depending on tumor location, mediastinoscopy, mediastinotomy, and thoracoscopy are the preferred diagnostic methods.
  • The importance of surgical treatment of germ cell tumors is determined by a negative concentration of beta-HCG and alpha-fetoprotein and in cases of residual tumor after chemotherapy.
  • Ninety-eight percent of neurogenic tumors in adults are benign and usually resected via thoracoscopy or thoracotomy, depending on location and size.
  • [MeSH-major] Lymphoma / surgery. Mediastinal Neoplasms / surgery. Neoplasms, Germ Cell and Embryonal / surgery. Thymoma / surgery. Thymus Neoplasms / surgery
  • [MeSH-minor] Adult. Age Factors. Child. Female. Humans. Incidence. Male. Mediastinoscopy. Mediastinum / pathology. Neoplasm Staging. Prognosis. Radiography. Thoracoscopy. Thoracotomy

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Thorac Surg. 1991 Jul;52(1):6-13 [2069465.001]
  • [Cites] J Thorac Cardiovasc Surg. 1996 Aug;112(2):376-84 [8751506.001]
  • [Cites] J Thorac Cardiovasc Surg. 1983 Nov;86(5):727-31 [6632945.001]
  • [Cites] Chest. 1991 Feb;99(2):472-9 [1846573.001]
  • [Cites] Ann Thorac Surg. 1966 Jul;2(4):532-9 [5934068.001]
  • [Cites] J Pediatr Surg. 1986 Jun;21(6):548-51 [2425069.001]
  • [Cites] Cancer. 1981 Jan 15;47(2):373-81 [7459826.001]
  • [Cites] Ann Thorac Surg. 2003 Sep;76(3):878-84; discussion 884-5 [12963221.001]
  • [Cites] Ann Thorac Surg. 2002 Aug;74(2):615-23 [12173869.001]
  • [Cites] Ann Thorac Surg. 1986 Sep;42(3):338-45 [3530162.001]
  • [Cites] Ann Surg. 1948 Mar;127(3):476-502 [17859095.001]
  • [Cites] Ann Thorac Surg. 1991 Jan;51(1):152-6 [1985561.001]
  • [Cites] Ann Thorac Surg. 1987 Sep;44(3):229-37 [2820323.001]
  • [Cites] Int J Cancer. 2003 Jul 1;105(4):546-51 [12712448.001]
  • [Cites] Ann Thorac Surg. 2001 Jul;72 (1):208-11 [11465181.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1864-73 [11919246.001]
  • [Cites] Surg Today. 2005;35(10):805-11 [16175459.001]
  • [Cites] J Surg Oncol. 1992 May;50(1):43-6 [1573893.001]
  • [Cites] J Thorac Cardiovasc Surg. 2003 Feb;125(2):434-6 [12579125.001]
  • [Cites] Am J Surg Pathol. 2001 Jan;25(1):103-10 [11145244.001]
  • [Cites] Ann Thorac Surg. 2003 Dec;76(6):1859-64; discussion 1864-5 [14667600.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1979 Jul 27;383(1):43-57 [157612.001]
  • [Cites] Cancer. 1997 Aug 15;80(4):681-90 [9264351.001]
  • [Cites] Ann Thorac Surg. 1995 Oct;60(4):943-6 [7574999.001]
  • [Cites] Thorax. 1978 Jun;33(3):359-67 [210531.001]
  • [Cites] Cancer. 1992 Jun 1;69(11):2755-60 [1373989.001]
  • [Cites] Ann Thorac Surg. 1995 Oct;60(4):908-13; discussion 914 [7574993.001]
  • [Cites] Ann Thorac Surg. 2004 May;77(5):1860-9 [15111216.001]
  • [Cites] Ann Surg. 1999 Oct;230(4):562-72; discussion 572-4 [10522726.001]
  • (PMID = 18058077.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 31
  •  go-up   go-down


64. Nakajima J: [Surgical therapy for elderly patients with mediastinal neoplasms except for thymic epithelial tumors]. Kyobu Geka; 2005 Jul;58(8 Suppl):745-50

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two of them had malignant neoplasms (a germ cell tumor and a malignant fibrous histiocytoma).
  • A 76-year-old patient with a malignant germ cell tumor had undergone reexploration because of persistent air leakage from the bronchopleural fistula.
  • Surgical procedures were practically performed to determine the pathological diagnosis or to treat the patients with pathologically benign neoplasms because of diverse biological behaviors of these mediastinal tumors.
  • [MeSH-minor] Age Factors. Aged. Aged, 80 and over. Combined Modality Therapy. Fatal Outcome. Female. Germinoma / diagnosis. Germinoma / surgery. Histiocytoma, Benign Fibrous / diagnosis. Histiocytoma, Benign Fibrous / surgery. Humans. Male. Postoperative Care. Prognosis. Retrospective Studies. Thoracoscopy. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16097630.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 13
  •  go-up   go-down


65. Carmignani L, Morabito A, Gadda F, Bozzini G, Rocco F, Colpi GM: Prognostic parameters in adult impalpable ultrasonographic lesions of the testicle. J Urol; 2005 Sep;174(3):1035-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histologically 15 of the lesions were Leydig cell tumors (31%), 12 (25%) seminomas, 7 (14.5%) nonseminomatous germ cell tumors, 2 (4.5%) Sertoli cell tumors, 12 (25%) benign forms (fibrosis, infarct, lipoma, mesothelial hyperplasia, adenomatoid tumor).
  • Dimension was particularly related to germ cell tumors (for dimensions between 16 and 32 mm relative risk ratio [RRR] = 13.97, p=0.0449).
  • In particular an interesting correlation was found between the dimensions of the lesion and the malignant pathology and between Leydig cell tumor and infertility.
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Follow-Up Studies. Humans. Infertility, Male / mortality. Infertility, Male / pathology. Infertility, Male / ultrasonography. Logistic Models. Male. Mathematical Computing. Middle Aged. Multivariate Analysis. Neoplasms, Germ Cell and Embryonal / mortality. Neoplasms, Germ Cell and Embryonal / pathology. Neoplasms, Germ Cell and Embryonal / ultrasonography. Prognosis. Retrospective Studies. Risk. Statistics as Topic. Survival Rate. Task Performance and Analysis

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16094042.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] United States
  •  go-up   go-down


66. Xian W, Miron A, Roh M, Semmel DR, Yassin Y, Garber J, Oliva E, Goodman A, Mehra K, Berkowitz RS, Crum CP, Quade BJ: The Li-Fraumeni syndrome (LFS): a model for the initiation of p53 signatures in the distal Fallopian tube. J Pathol; 2010 Jan;220(1):17-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A candidate early precursor to pelvic serous cancer, the 'p53 signature', is commonly found in the benign mucosa of the distal Fallopian tube and harbours p53 mutations and evidence of DNA damage.
  • We examined tubes from women with pre-existing (germ-line) mutations in p53 [Li-Fraumeni syndrome (LFS)] for evidence of this precursor.

  • Genetic Alliance. consumer health - Li Fraumeni syndrome.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Obstet Gynecol. 2005 Dec;106(6):1327-34 [16319259.001]
  • [Cites] Mol Med Today. 1997 Sep;3(9):390-5 [9302689.001]
  • [Cites] J Pathol. 2007 Jan;211(1):26-35 [17117391.001]
  • [Cites] Am J Surg Pathol. 2007 Feb;31(2):161-9 [17255760.001]
  • [Cites] Cell. 2007 May 4;129(3):523-36 [17482546.001]
  • [Cites] J Clin Oncol. 2007 Sep 1;25(25):3985-90 [17761984.001]
  • [Cites] Int J Gynecol Pathol. 2008 Jan;27(1):1-9 [18156967.001]
  • [Cites] BMC Cancer. 2008;8:17 [18208621.001]
  • [Cites] Gynecol Oncol. 2008 May;109(2):168-73 [18342932.001]
  • [Cites] Genes Dev. 2008 May 15;22(10):1337-44 [18483220.001]
  • [Cites] Expert Rev Mol Med. 2008;10:e22 [18671886.001]
  • [Cites] J Clin Oncol. 2008 Sep 1;26(25):4160-5 [18757330.001]
  • [Cites] Gynecol Oncol. 2008 Nov;111(2):226-32 [18718648.001]
  • [Cites] Lancet Oncol. 2008 Dec;9(12):1191-7 [19038766.001]
  • [Cites] Pediatr Radiol. 2009 Feb;39 Suppl 1:S27-31 [19083227.001]
  • [Cites] Cell Cycle. 2009 Mar 1;8(5):731-5 [19221485.001]
  • [Cites] Cancer Res. 2009 Apr 15;69(8):3625-33 [19336573.001]
  • [Cites] Histopathology. 2001 May;38(5):481-2 [11422490.001]
  • [Cites] In Vivo. 1999 Jan-Feb;13(1):99-106 [10218141.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):127-32 [15625367.001]
  • [Cites] Mol Cell. 2005 Jun 10;18(6):617-22 [15949437.001]
  • [Cites] Gynecol Oncol. 2006 Jan;100(1):58-64 [16137750.001]
  • [Cites] Fam Cancer. 2009;8(4):339-46 [19340607.001]
  • [Cites] Cancer. 2001 Aug 15;92(4):787-95 [11550149.001]
  • [Cites] J Pathol. 2001 Nov;195(4):451-6 [11745677.001]
  • [Cites] Nat Rev Cancer. 2001 Nov;1(2):157-62 [11905807.001]
  • [Cites] N Engl J Med. 2002 Nov 14;347(20):1593-603 [12432047.001]
  • [Cites] Gynecol Oncol. 2002 Oct;87(1):52-6 [12468342.001]
  • [Cites] Am J Obstet Gynecol. 2004 Sep;191(3):718-32 [15467531.001]
  • [Cites] Cancer. 1994 Apr 1;73(7):1859-64 [8137211.001]
  • [CommentIn] J Pathol. 2010 Jan;220(1):5-6 [19882674.001]
  • (PMID = 19834951.001).
  • [ISSN] 1096-9896
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R21 CA124688; United States / NCI NIH HHS / CA / R21 CA124688-02S1; United States / NCI NIH HHS / CA / 1R21CA124688-01A1; United States / NCI NIH HHS / CA / P50CA10500
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ NIHMS184416; NLM/ PMC2841524
  •  go-up   go-down


67. Chierigo P, Puccetti O, Visonà A, Bassan F, Rahmati M, Lazzarotto M, Franzolin N: [High alpha-fetoprotein persistence after orchiectomy. On a case of uncommon etiology]. Urologia; 2010 Oct-Dec;77 Suppl 17:27-31

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The existence of this clinically benign condition needs to be considered in both children and adults with unexplained and persistent elevation of AFP, e.g. those diagnosed or suspected for germ cell tumor.
  • [MeSH-minor] Adenoma / complications. Adrenal Gland Neoplasms / complications. Adult. Diagnosis, Differential. Genes, Dominant. Humans. Ischemia / surgery. Male. Neoplasms, Germ Cell and Embryonal / diagnosis. Postoperative Period. Testicular Neoplasms / diagnosis. Testis / blood supply. Testis / pathology. Unnecessary Procedures

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21308671.001).
  • [ISSN] 0391-5603
  • [Journal-full-title] Urologia
  • [ISO-abbreviation] Urologia
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / AFP protein, human; 0 / alpha-Fetoproteins
  •  go-up   go-down


68. Derouiche A, Ouni A, Kourda N, Hentati H, Ben Slama MR, Chebil M: Cystic nephroma in the adult: pathological aspects and therapeutic implications. Pathologica; 2007 Dec;99(6):446-9
MedlinePlus Health Information. consumer health - Kidney Cysts.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cystic nephroma is a benign renal neoplasm.
  • The differential diagnoses of Cystic nephroma are recently described mixed epithelial and stromal tumours of the kidney and cystic renal cell carcinoma.
  • The Authors report three cases of Cystic nephroma and illustrate the clinical, radiological and histological features of this renal neoplasm.
  • [MeSH-minor] Adult. Cystadenocarcinoma / diagnosis. Echinococcosis / diagnosis. Female. Humans. Male. Middle Aged. Neoplasms, Germ Cell and Embryonal / diagnosis. Nephrectomy. Wilms Tumor / classification. Wilms Tumor / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18416340.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


69. Swamy GG, Satyanarayana N: Clinicopathological analysis of ovarian tumors--a study on five years samples. Nepal Med Coll J; 2010 Dec;12(4):221-3
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among 120 cases, majority 86 (71.6%) were benign, but alarming number 30 (25.0%) were malignant, remaining 4 cases were borderline.
  • The commonest benign tumor was serous cyst adenoma, while; the commonest malignant tumors were granulosa cell tumor and endometrial carcinoma.
  • Epithelial tumors were commonest variety of ovarian tumors followed by germ cell tumors.
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Cystadenoma, Serous / pathology. Epithelium / surgery. Female. Granulosa Cell Tumor / pathology. Humans. Middle Aged. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21744762.001).
  • [Journal-full-title] Nepal Medical College journal : NMCJ
  • [ISO-abbreviation] Nepal Med Coll J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nepal
  •  go-up   go-down


70. Mitra A, Jameson C, Barbachano Y, Sanchez L, Kote-Jarai Z, Peock S, Sodha N, Bancroft E, Fletcher A, Cooper C, Easton D, IMPACT Steering Committee and IMPACT and EMBRACE Collaborators, Eeles R, Foster CS: Overexpression of RAD51 occurs in aggressive prostatic cancer. Histopathology; 2009 Dec;55(6):696-704
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RAD51 protein expression in the cytoplasm and nuclei of the benign tissues was significantly less than in the malignant tissues (P < 0.001).
  • In all cancers, cytoplasmic expression of RAD51 was more prevalent and associated with higher Gleason score (P < 0.05) irrespective of BRCA mutational status, than its expression in benign tissues (P < 0.001).
  • Although nuclear immunoreactivity was not observed in BRCA-associated cancers with Gleason score < or =7, it was significantly increased in all other groups of prostatic cancers when compared with benign tissues (P < 0.001).
  • CONCLUSIONS: RAD51 protein is strongly expressed in high-grade prostatic cancers, whether sporadic or associated with BRCA germ-line mutations.
  • [MeSH-major] BRCA1 Protein / genetics. BRCA2 Protein / genetics. Germ-Line Mutation / genetics. Prostatic Neoplasms / metabolism. Rad51 Recombinase / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / genetics. Cell Count. Gene Expression Regulation, Neoplastic. Genetic Predisposition to Disease. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Proteins / genetics. Neoplasm Proteins / metabolism. Severity of Illness Index

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathologe. 1987 May;8(3):138-40 [3303008.001]
  • [Cites] Mol Cell Biol. 2004 Nov;24(21):9305-16 [15485900.001]
  • [Cites] Nat Genet. 2009 Oct;41(10):1058-60 [19767752.001]
  • [Cites] Nat Genet. 2009 Oct;41(10):1116-21 [19767753.001]
  • [Cites] Br J Cancer. 2009 Oct 20;101(8):1469-80 [19826428.001]
  • [Cites] Nat Rev Cancer. 2009 Nov;9(11):821-9 [19776747.001]
  • [Cites] J Biol Chem. 2009 Nov 13;284(46):31945-52 [19783859.001]
  • [Cites] J Natl Cancer Inst. 1997 Jan 1;89(1):66-71 [8978408.001]
  • [Cites] Cell. 1997 Jan 24;88(2):265-75 [9008167.001]
  • [Cites] Cell. 1997 Aug 8;90(3):425-35 [9267023.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Oct 28;94(22):12075-80 [9342365.001]
  • [Cites] J Natl Cancer Inst. 1999 Aug 4;91(15):1310-6 [10433620.001]
  • [Cites] Cancer Res. 1999 Aug 1;59(15):3547-51 [10446958.001]
  • [Cites] Nat Cell Biol. 2005 Feb;7(2):195-201 [15665856.001]
  • [Cites] J Biol Chem. 2005 Mar 4;280(9):8051-9 [15611070.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Br J Cancer. 2005 Jul 11;93(1):137-43 [15956972.001]
  • [Cites] Br J Cancer. 2005 Aug 22;93(4):478-82 [16091762.001]
  • [Cites] Nat Struct Mol Biol. 2005 Oct;12(10):902-9 [16186822.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7503-11 [16234517.001]
  • [Cites] J Cell Biochem. 2005 Dec 15;96(6):1095-109 [16215984.001]
  • [Cites] Hum Mutat. 2006 Jan;27(1):14-20 [16278824.001]
  • [Cites] Eur J Gynaecol Oncol. 2005;26(6):589-98 [16398215.001]
  • [Cites] J Cell Biochem. 2006 Feb 15;97(3):433-47 [16267836.001]
  • [Cites] Int J Oncol. 2006 May;28(5):1113-9 [16596227.001]
  • [Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):929-35 [17565157.001]
  • [Cites] BJU Int. 2007 Dec;100(6):1240-4 [17979924.001]
  • [Cites] Br J Cancer. 2008 Jan 29;98(2):502-7 [18182994.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Br J Cancer. 2008 Apr 22;98(8):1457-66 [18349832.001]
  • [Cites] Hum Mol Genet. 2008 Oct 15;17(R2):R109-15 [18852198.001]
  • [Cites] BJU Int. 2009 Jul;104(1):20-4 [19239456.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Sep;18(9):2460-7 [19723918.001]
  • [Cites] Oncogene. 2000 May 25;19(23):2791-5 [10851081.001]
  • [Cites] Int J Cancer. 2000 Dec 15;88(6):907-13 [11093813.001]
  • [Cites] Oncogene. 2002 Jul 25;21(32):5002-5 [12118380.001]
  • [Cites] J Natl Cancer Inst. 2002 Sep 18;94(18):1358-65 [12237281.001]
  • [Cites] Am J Hum Genet. 2003 Jan;72(1):1-12 [12474142.001]
  • [Cites] Oncogene. 2003 Feb 27;22(8):1115-23 [12606939.001]
  • [Cites] Exp Cell Res. 2003 Jun 10;286(2):298-307 [12749858.001]
  • [Cites] Oncogene. 2004 Jan 15;23(2):546-53 [14724582.001]
  • [Cites] J Mol Biol. 2004 Jun 11;339(4):797-804 [15165851.001]
  • [Cites] J Pathol. 1994 Aug;173(4):371-9 [7965396.001]
  • (PMID = 20002770.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / 10118; United Kingdom / Cancer Research UK / / A3354; United Kingdom / Cancer Research UK / / C5047/A8385
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BRCA1 Protein; 0 / BRCA2 Protein; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; EC 2.7.7.- / RAD51 protein, human; EC 2.7.7.- / Rad51 Recombinase
  • [Other-IDs] NLM/ PMC2856636; NLM/ UKMS28917
  •  go-up   go-down


71. Ra YJ, Bae MJ, Kim YS, Choi KU: Difficulties in diagnosis and treatment of thymic adenocarcinoma producing beta-human chorionic gonadotropin in anterior mediastinum. Interact Cardiovasc Thorac Surg; 2010 Jul;11(1):114-6
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since the beta-human chorionic gonadotropin (beta-hCG) level was increased to 20.46 mIU/ml on the preoperative blood test, incisional biopsy was performed through a Chamberlain incision to rule out the mediastinal germ cell tumors.
  • After diagnosing a benign mass on the postoperative pathological examination of the incisional biopsy specimen, total thymectomy that included the mass was performed via a full sternotomy.
  • On the pathological examination after the second operation, the tumor was diagnosed as thymic adenocarcinoma producing beta-hCG, and the tumor had originated from the thymus.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Biomarkers, Tumor / blood. Chorionic Gonadotropin, beta Subunit, Human / blood. Mediastinal Neoplasms / secondary. Mediastinal Neoplasms / surgery. Thoracic Surgical Procedures. Thymus Neoplasms / pathology. Thymus Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20421278.001).
  • [ISSN] 1569-9285
  • [Journal-full-title] Interactive cardiovascular and thoracic surgery
  • [ISO-abbreviation] Interact Cardiovasc Thorac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chorionic Gonadotropin, beta Subunit, Human
  •  go-up   go-down


72. Schultz KA, Sencer SF, Messinger Y, Neglia JP, Steiner ME: Pediatric ovarian tumors: a review of 67 cases. Pediatr Blood Cancer; 2005 Feb;44(2):167-73
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Thirty patients had benign tumors.
  • Thirty-seven patients had malignant tumors: 11 immature teratomas, seven malignant mixed germ cell tumors, seven juvenile granulosa cell tumors, five dysgerminomas, two endodermal sinus tumors, two serous papillary cystadenocarcinomas, one small cell carcinoma, one anaplastic sex-cord tumor, and one undifferentiated sarcoma.
  • Torsion was seen more often in patients with benign tumors (23 vs. 8%); two patients had both torsion and acute appendicitis.
  • The neoplasm was an incidental finding in 12 patients.
  • [MeSH-minor] Adolescent. Biomarkers, Tumor / blood. Child. Child, Preschool. Chromosome Aberrations. Female. Humans. Infant. Infant, Newborn. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15490488.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


73. Kumamoto H, Ohki K, Ooya K: Expression of p63 and p73 in ameloblastomas. J Oral Pathol Med; 2005 Apr;34(4):220-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Tissue specimens of nine tooth germs and 48 benign and five malignant ameloblastomas were examined by immunohistochemistry and reverse transcriptase-polymerase chain reaction (RT-PCR) for the expression of p63 and p73.
  • RESULTS: Immunoreactivity for p63 and p73 was evident in epithelial cells neighboring the basement membrane in developing and neoplastic odontogenic tissues. p63 expression in desmoplastic ameloblastomas was significantly higher than in acanthomatous and granular cell ameloblastomas, and ameloblastic carcinomas showed higher p63 expression than metastasizing ameloblastomas. p73 expression was significantly higher in plexiform ameloblastomas than in follicular ameloblastomas, and basal cell ameloblastomas showed higher p73 expression than granular cell ameloblastomas. mRNA transcripts for Delta Np63 and TAp73 were detected in all developing and neoplastic odontogenic tissues.
  • [MeSH-major] Ameloblastoma / genetics. Apoptosis / genetics. DNA-Binding Proteins / genetics. Genes, Tumor Suppressor. Nuclear Proteins / genetics. Phosphoproteins / genetics. Trans-Activators / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Basement Membrane / metabolism. Cell Differentiation / genetics. Cell Proliferation. Epithelial Cells / metabolism. Gene Expression Regulation, Neoplastic / genetics. Humans. Immunohistochemistry. Protein Isoforms / genetics. Reverse Transcriptase Polymerase Chain Reaction. Tooth Germ / metabolism. Transcription Factors. Tumor Suppressor Protein p53 / genetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15752257.001).
  • [ISSN] 0904-2512
  • [Journal-full-title] Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • [ISO-abbreviation] J. Oral Pathol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Phosphoproteins; 0 / Protein Isoforms; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; 0 / tumor suppressor protein p73
  •  go-up   go-down


74. Harms D, Zahn S, Göbel U, Schneider DT: Pathology and molecular biology of teratomas in childhood and adolescence. Klin Padiatr; 2006 Nov-Dec;218(6):296-302
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The biologic behaviour of teratomas depends on various interdependent clinical and epidemiologic variables such as the age at diagnosis, sex, tumor site, histology which all correlate to different cytogenetic and molecular biologic aberrations.
  • Thus, testicular teratomas of infancy are generally benign.
  • In contrast, postpubertal testicular teratomas can present as clinically malignant tumors and may show complex cytogenetic aberrations such as the isochromosome 12p, which is pathognomonic of malignant germ cell tumors.
  • Notably, teratomas of both age groups show an at least partial erasure of the genomic imprinting, correlating with their origin from primordial germ cells.
  • The Kiel Pediatric Tumor Registry includes 541 teratoma specimens, and among these, the most frequent tumor sites (in descending order) are: the sacrococcygeal region (33.8 %), the ovaries (31.2 %) and the testes (10.5 %).
  • The WHO classification of germ cell tumors distinguishes mature and immature teratomas as well as teratomas with malignant transformation.
  • The frequency of additional microscopic foci of malignant yolk sac tumor correlates with the grade of immaturity.
  • In sacrococcygeal teratomas, the yolk sac tumor microfoci may give rise to a malignant relapse after incomplete resection.
  • Here, molecular genetic analysis has demonstrated the origin of the somatic malignancy from a malignant transformation within the germ cell tumor with retention of the cytogenetic changes characteristic of malignant germ cell tumors.
  • [MeSH-minor] Adolescent. Adult. Age Factors. Child. Chromosome Aberrations. Chromosome Deletion. Cytogenetic Analysis. Endodermal Sinus Tumor / epidemiology. Endodermal Sinus Tumor / pathology. Female. Germany / epidemiology. Heterozygote. Humans. Incidence. Infant. Infant, Newborn. Male. Ovary / pathology. Puberty. Testis / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17080330.001).
  • [ISSN] 0300-8630
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


75. Ylisaukko-oja SK, Cybulski C, Lehtonen R, Kiuru M, Matyjasik J, Szymañska A, Szymañska-Pasternak J, Dyrskjot L, Butzow R, Orntoft TF, Launonen V, Lubiñski J, Aaltonen LA: Germline fumarate hydratase mutations in patients with ovarian mucinous cystadenoma. Eur J Hum Genet; 2006 Jul;14(7):880-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Germline mutations in the fumarate hydratase (FH) gene were recently shown to predispose to the dominantly inherited syndrome, hereditary leiomyomatosis and renal cell cancer (HLRCC).
  • HLRCC is characterized by benign leiomyomas of the skin and the uterus, renal cell carcinoma, and uterine leiomyosarcoma.
  • The aim of this study was to identify new families with FH mutations, and to further examine the tumor spectrum associated with FH mutations.
  • These results suggest that benign ovarian tumors may be associated with HLRCC.
  • [MeSH-major] Cystadenoma, Mucinous / genetics. Fumarate Hydratase / genetics. Germ-Line Mutation. Neoplastic Syndromes, Hereditary / genetics. Ovarian Neoplasms / genetics
  • [MeSH-minor] Carcinoma, Renal Cell / genetics. Cystadenocarcinoma, Mucinous / genetics. Female. Genes, Dominant. Humans. Kidney Neoplasms / genetics. Leiomyoma / genetics. Male. Neoplasms / genetics. Skin Neoplasms / genetics. Urinary Bladder Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16639410.001).
  • [ISSN] 1018-4813
  • [Journal-full-title] European journal of human genetics : EJHG
  • [ISO-abbreviation] Eur. J. Hum. Genet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 4.2.1.2 / Fumarate Hydratase
  •  go-up   go-down


76. Brems H, Park C, Maertens O, Pemov A, Messiaen L, Upadhyaya M, Claes K, Beert E, Peeters K, Mautner V, Sloan JL, Yao L, Lee CC, Sciot R, De Smet L, Legius E, Stewart DR: Glomus tumors in neurofibromatosis type 1: genetic, functional, and clinical evidence of a novel association. Cancer Res; 2009 Sep 15;69(18):7393-401
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neurofibromatosis type 1 (NF1) is a common disorder that arises secondary to mutations in the tumor suppressor gene NF1.
  • Glomus tumors are small, benign but painful tumors that originate from the glomus body, a thermoregulatory shunt concentrated in the fingers and toes.
  • In 12 NF1-associated glomus tumors, we used cell culture and laser capture microdissection to isolate DNA.
  • Genetic analysis showed germ line and somatic NF1 mutations in seven tumors.
  • Glomus tumors of the fingers or toes should be considered as part of the tumor spectrum of NF1.
  • [MeSH-major] Glomus Tumor / genetics. Neurofibromatosis 1 / genetics
  • [MeSH-minor] Actins / biosynthesis. Adolescent. Adult. Child. Comparative Genomic Hybridization. Female. Fibroblasts / metabolism. Fibroblasts / physiology. Gene Dosage. Gene Silencing. Genes, Neurofibromatosis 1. Humans. MAP Kinase Signaling System. Male. Middle Aged. Polymerase Chain Reaction. Receptors, Androgen / metabolism. Skin / cytology. Tumor Cells, Cultured. Young Adult. ras Proteins / metabolism

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 1.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Mutat. 1999;14(5):387-93 [10533064.001]
  • [Cites] N Engl J Med. 2002 Sep 12;347(11):854-5; author reply 854-5 [12226162.001]
  • [Cites] Leukemia. 2000 Jan;14(1):207-12 [10637497.001]
  • [Cites] Hum Mutat. 2000;15(6):541-55 [10862084.001]
  • [Cites] J Dermatol. 2000 Jun;27(6):418-9 [10920593.001]
  • [Cites] Cell. 2001 Feb 23;104(4):593-604 [11239415.001]
  • [Cites] Genes Dev. 2003 Feb 15;17(4):449-54 [12600938.001]
  • [Cites] Nat Genet. 2004 Apr;36(4):411-6 [15004558.001]
  • [Cites] Curr Hematol Rep. 2004 May;3(3):203-9 [15087069.001]
  • [Cites] Nucleic Acids Res. 2004;32(8):2529-40 [15133121.001]
  • [Cites] J Hand Surg Am. 1977 Jul;2(4):261-5 [197147.001]
  • [Cites] Cancer. 1982 Oct 15;50(8):1601-7 [6288219.001]
  • [Cites] Cancer Res. 1985 Apr;45(4):1437-43 [2983882.001]
  • [Cites] Science. 1990 Jul 13;249(4965):181-6 [2134734.001]
  • [Cites] Cell. 1990 Nov 16;63(4):843-9 [2121370.001]
  • [Cites] Nucleic Acids Res. 1991 Jul 11;19(13):3764 [1906608.001]
  • [Cites] Hum Mol Genet. 1993 Jun;2(6):725-30 [8353492.001]
  • [Cites] Hum Genet. 1993 Oct;92(4):429-30 [8225327.001]
  • [Cites] Hum Genet. 1994 Mar;93(3):351-2 [8125490.001]
  • [Cites] J Am Acad Dermatol. 1995 Feb;32(2 Pt 1):277-8 [7829715.001]
  • [Cites] J Hand Surg Br. 1996 Apr;21(2):257-60 [8732413.001]
  • [Cites] Am J Hum Genet. 1997 Sep;61(3):512-9 [9326316.001]
  • [Cites] Hum Genet. 1999 Jan;104(1):49-55 [10071192.001]
  • [Cites] Cell. 1999 Mar 5;96(5):737-49 [10089888.001]
  • [Cites] J Dermatol. 1999 Aug;26(8):535-7 [10487011.001]
  • [Cites] J Heart Lung Transplant. 2005 Nov;24(11):1915-29 [16297800.001]
  • [Cites] Hum Mol Genet. 2006 Mar 15;15(6):1015-23 [16461335.001]
  • [Cites] J Hand Surg Am. 2006 Oct;31(8):1397-400 [17027805.001]
  • [Cites] Matrix Biol. 2007 Jan;26(1):30-41 [17074475.001]
  • [Cites] PLoS Comput Biol. 2007 Apr 20;3(4):e72 [17447839.001]
  • [Cites] Fam Cancer. 2007;6(1):21-34 [16944272.001]
  • [Cites] Am J Hum Genet. 2007 Aug;81(2):243-51 [17668375.001]
  • [Cites] Hum Mutat. 2008 Jan;29(1):74-82 [17960768.001]
  • [Cites] Mol Cancer. 2008;7:8 [18211683.001]
  • [Cites] J Med Genet. 2008 Oct;45(10):622-31 [18511569.001]
  • [Cites] Lancet Oncol. 2009 May;10(5):508-15 [19410195.001]
  • [Cites] Nucleic Acids Res. 2002 Jun 15;30(12):e57 [12060695.001]
  • [Cites] J Med Genet. 2002 Aug;39(8):e45 [12161612.001]
  • [ErratumIn] Cancer Res. 2009 Oct 15;69(20):8216. Messia, Ludwine [corrected to Messiaen, Ludwine]
  • (PMID = 19738042.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 HG200329-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ACTA2 protein, human; 0 / Actins; 0 / Receptors, Androgen; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ NIHMS135382; NLM/ PMC2747722
  •  go-up   go-down


77. Yu DK, Joo YH, Cho KH: Trichoblastoma with apocrine and sebaceous differentiation. Am J Dermatopathol; 2005 Feb;27(1):6-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Trichoblastoma is a rare, benign tumor that differentiates toward the hair germ, the embryonic precursor of a hair follicle.
  • An immunohistochemical study showed that the neoplasm, or areas in it, stained positive for low molecular cytokeratin, high molecular cytokeratin, EMA, S-100, and GCDFP-15.
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Cell Transformation, Neoplastic. Female. Humans. Immunohistochemistry. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hair Problems.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15677969.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


78. Riethdorf S, Reimers N, Assmann V, Kornfeld JW, Terracciano L, Sauter G, Pantel K: High incidence of EMMPRIN expression in human tumors. Int J Cancer; 2006 Oct 15;119(8):1800-10

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Extracellular matrix metalloproteinase inducer expressed by tumor cells stimulates peritumoral fibroblasts to produce matrix metalloproteinases, thus contributing to tumor invasion and metastasis.
  • EMMPRIN expression was detected immunohistochemically using monoclonal antibodies MEM-M6/1 and HIM6 and tissue microarrays with 2,348 and 608 tissue samples from 129 distinct tumor types and 76 different normal tissues, respectively.
  • EMMPRIN expression was found in 112 of 129 tumor entities analyzed with malignant tumors being EMMPRIN positive more frequently than benign tumors.
  • A remarkable heterogeneity in EMMPRIN expression between tumor entities was observed.
  • Among others, squamous-cell carcinomas (60-100%), pancreatic (87%), chromophobic kidney (83%), hepatocellular (83%) or medullary breast (83%) adenocarcinomas as well as glioblastoma multiforme (79%) presented with a particular high incidence of EMMPRIN expression.
  • There were a limited number of EMMPRIN-positive normal cell types including proliferatively active and differentiating epithelial cells, germ cells, myocardial cells in the left heart ventricle or vascular endothelial cells of the brain.
  • [MeSH-minor] Carbohydrate Metabolism. Cell Line, Tumor. Female. Humans. Immunohistochemistry. Male. Protein Isoforms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16721788.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Isoforms; 136894-56-9 / Antigens, CD147
  •  go-up   go-down


79. Las Heras F, Pritzker KP, Colgan TJ: Chordoma arising in a mature cystic teratoma of the ovary: a case report. Pathol Res Pract; 2007;203(6):467-71
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mature cystic teratoma of the ovary (MCTO) is the most common type of ovarian teratoma and also the most frequent tumor originating from germ cells.
  • It is usually diagnosed in early adulthood and, by definition, is composed of well-differentiated tissues, which originate from all three germ cell layers.
  • Squamous cell carcinoma is the most common malignancy arising in these otherwise benign tumors.
  • [MeSH-major] Cell Differentiation. Cell Transformation, Neoplastic / pathology. Chordoma / diagnosis. Ovarian Neoplasms / diagnosis. Teratoma / diagnosis
  • [MeSH-minor] Adult. Chromosomes, Human, Pair 7. Chromosomes, Human, X. Diagnosis, Differential. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Keratins / analysis. Ki-67 Antigen / analysis. Mosaicism. Mucin-1 / analysis. S100 Proteins / analysis. Tumor Suppressor Protein p53 / analysis. Vimentin / analysis

  • Genetic Alliance. consumer health - Chordoma.
  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17418959.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Mucin-1; 0 / S100 Proteins; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 0 / Vimentin; 68238-35-7 / Keratins
  •  go-up   go-down


80. Murakami T, Sano F, Huang Y, Komiya A, Baba M, Osada Y, Nagashima Y, Kondo K, Nakaigawa N, Miura T, Kubota Y, Yao M, Kishida T: Identification and characterization of Birt-Hogg-Dubé associated renal carcinoma. J Pathol; 2007 Apr;211(5):524-31
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Birt-Hogg-Dubé (BHD) gene is responsible for BHD syndrome, a rare autosomal dominant disease, characterized by benign hair follicle tumours, spontaneous pneumothorax and renal neoplasms with diverse histology.
  • The germline-mutated patient suffered from solitary renal cell carcinoma (RCC) but did not have any other BHD manifestations or family history.
  • [MeSH-major] Carcinoma, Renal Cell / genetics. Kidney Neoplasms / genetics. Neoplasm Proteins / genetics. Proteins / genetics. Proto-Oncogene Proteins / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Cluster Analysis. Eosinophilia / genetics. Eosinophilia / pathology. Gene Expression Regulation, Neoplastic / genetics. Genes, Tumor Suppressor / physiology. Germ-Line Mutation / genetics. Hair Diseases / genetics. Hair Diseases / pathology. Hair Follicle / pathology. Humans. Loss of Heterozygosity / genetics. Mutation / genetics. Pneumothorax / genetics. Pneumothorax / pathology. Polymerase Chain Reaction / methods. Polymorphism, Single-Stranded Conformational. Syndrome

  • Genetic Alliance. consumer health - Birt-Hogg-Dube Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
  • (PMID = 17323425.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / FLCN protein, human; 0 / Neoplasm Proteins; 0 / Proteins; 0 / Proto-Oncogene Proteins; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


81. Kumamoto H, Ooya K: Immunohistochemical detection of insulin-like growth factors, platelet-derived growth factor, and their receptors in ameloblastic tumors. J Oral Pathol Med; 2007 Apr;36(4):198-206
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Immunohistochemical reactivity for IGFs, PDGF chains, and their receptors was detected predominantly in odontogenic epithelial cells near the basement membrane in tooth germs and in benign and malignant ameloblastic tumors.
  • Malignant ameloblastic tumors showed higher reactivity for PDGF chains than benign ameloblastomas and higher reactivity for platelet-derived growth factor receptors than tooth germs.
  • CONCLUSION: Expression of IGFs, PDGF, and their receptors in tooth germs and ameloblastic tumors suggests that these growth factor signals contribute to cell proliferation or survival in both normal and neoplastic odontogenic tissues.
  • Altered expression of the ligands and receptors in ameloblastic tumors may be involved in oncogenesis, malignant potential, and tumor cell differentiation.
  • [MeSH-major] Ameloblastoma / metabolism. Insulin-Like Growth Factor I / biosynthesis. Insulin-Like Growth Factor II / biosynthesis. Jaw Neoplasms / metabolism. Platelet-Derived Growth Factor / biosynthesis. Tooth Germ / metabolism
  • [MeSH-minor] Cell Differentiation. Cell Proliferation. Humans. Immunohistochemistry. Proto-Oncogene Proteins c-sis / biosynthesis. Receptor, Platelet-Derived Growth Factor alpha / biosynthesis. Receptor, Platelet-Derived Growth Factor beta / biosynthesis. Receptors, Platelet-Derived Growth Factor / biosynthesis. Receptors, Somatomedin / biosynthesis. Up-Regulation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17391297.001).
  • [ISSN] 0904-2512
  • [Journal-full-title] Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • [ISO-abbreviation] J. Oral Pathol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Platelet-Derived Growth Factor; 0 / Proto-Oncogene Proteins c-sis; 0 / Receptors, Somatomedin; 0 / platelet-derived growth factor A; 67763-96-6 / Insulin-Like Growth Factor I; 67763-97-7 / Insulin-Like Growth Factor II; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta; EC 2.7.10.1 / Receptors, Platelet-Derived Growth Factor
  •  go-up   go-down


82. Hoekzema R, Zonneveld IM, van der Wal AC: Type 2 segmental glomangiomas. Dermatol Online J; 2010;16(1):8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glomangiomas of the skin, currently named glomuvenous malformations (GVMs), are benign vascular lesions composed of thin-walled distorted blood vessels, surrounded by variable rows of glomus cells.
  • Glomuvenous malformations occur after both alleles of the gene encoding for glomulin, a molecule involved in smooth muscle cell differentiation, are hit by a loss-of-function mutation.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / genetics. Glomus Tumor / pathology. Neoplasms, Multiple Primary / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Biopsy. Germ-Line Mutation. Humans. Loss of Heterozygosity. Male. Myocytes, Smooth Muscle / pathology. Thigh. Thorax. Wrist

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20137750.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / GLMN protein, human
  •  go-up   go-down


83. Ciotti P, Garuti A, Gulli R, Ballestrero A, Bellone E, Mandich P: Germline mutations in the von Hippel-Lindau gene in Italian patients. Eur J Med Genet; 2009 Sep-Oct;52(5):311-4
SciCrunch. Clinical Genomic Database: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumours, most frequently retinal, cerebellar, and spinal hemangioblastoma, renal cell carcinoma, pheochromocytoma, and pancreatic tumours.
  • [MeSH-major] Genes. Germ-Line Mutation. Von Hippel-Lindau Tumor Suppressor Protein / genetics. von Hippel-Lindau Disease / genetics

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19464396.001).
  • [ISSN] 1878-0849
  • [Journal-full-title] European journal of medical genetics
  • [ISO-abbreviation] Eur J Med Genet
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 9007-49-2 / DNA; EC 6.3.2.19 / VHL protein, human; EC 6.3.2.19 / Von Hippel-Lindau Tumor Suppressor Protein
  •  go-up   go-down


84. Cheng L, Zhang S, MacLennan GT, Poulos CK, Sung MT, Beck SD, Foster RS: Interphase fluorescence in situ hybridization analysis of chromosome 12p abnormalities is useful for distinguishing epidermoid cysts of the testis from pure mature teratoma. Clin Cancer Res; 2006 Oct 1;12(19):5668-72
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The distinction of epidermoid cyst of the testis from teratoma is of critical importance because the former is benign and the latter is a malignant tumor that may have associated metastasis of either teratomatous or non-teratomatous germ cell tumor types.
  • Chromosome 12p abnormalities are seen in the vast majority of testicular germ cell tumors of adults and are present in all histologic subtypes.
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Humans. Interphase. Karyotyping. Male. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17020968.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Oltmann SC, Garcia N, Barber R, Huang R, Hicks B, Fischer A: Can we preoperatively risk stratify ovarian masses for malignancy? J Pediatr Surg; 2010 Jan;45(1):130-4
MedlinePlus Health Information. consumer health - Ovarian Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: A total of 424 patients were identified, with a mean age 12.5 years (range, 1 day to 19 years), without an age disparity between benign (12.54 years, 89%) and malignant (11.8 years, 11%) cases.
  • Imaging of benign neoplasms had a mean size of 8 cm (range, 0.9-36 cm) compared with malignancies at 17.3 cm (6.2-50 cm, P < .001).
  • The malignancies (n = 46) included germ cell (50%, n = 23), stromal (28%, n = 13), epithelial (17%, n = 8), and other (4%, n = 2).
  • Tumor markers obtained in 71% of malignancies were elevated in only 54%, whereas 6.5% of those sent in benign cases were similarly elevated.
  • Tumor markers, positive or negative, were not conclusive in all cases but useful for postoperative surveillance.
  • [MeSH-minor] Abdominal Pain / diagnosis. Age Factors. Biomarkers, Tumor / blood. CA-125 Antigen / blood. Carcinoembryonic Antigen / blood. Child. Child, Preschool. Confidence Intervals. Diagnosis, Differential. Female. Humans. Infant. Neoplasm Staging. Neoplasms / blood. Neoplasms / diagnosis. Neoplasms / surgery. Ovary / pathology. Ovary / surgery. Prognosis. Puberty, Precocious / diagnosis. Risk Assessment

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20105592.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Carcinoembryonic Antigen
  •  go-up   go-down


86. Baba M, Hong SB, Sharma N, Warren MB, Nickerson ML, Iwamatsu A, Esposito D, Gillette WK, Hopkins RF 3rd, Hartley JL, Furihata M, Oishi S, Zhen W, Burke TR Jr, Linehan WM, Schmidt LS, Zbar B: Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc Natl Acad Sci U S A; 2006 Oct 17;103(42):15552-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Birt-Hogg-Dubé syndrome, a hamartoma disorder characterized by benign tumors of the hair follicle, lung cysts, and renal neoplasia, is caused by germ-line mutations in the BHD(FLCN) gene, which encodes a tumor-suppressor protein, folliculin (FLCN), with unknown function.
  • The tumor-suppressor proteins encoded by genes responsible for several other hamartoma syndromes, LKB1, TSC1/2, and PTEN, have been shown to be involved in the mammalian target of rapamycin (mTOR) signaling pathway.

  • COS Scholar Universe. author profiles.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - UOK257-2 (CVCL_1D69) .
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - UOK257 (CVCL_S717) .
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. HGNC: Data: Gene Annotation .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem J. 2000 Feb 1;345 Pt 3:437-43 [10642499.001]
  • [Cites] Dev Biol. 2006 Mar 15;291(2):227-38 [16443210.001]
  • [Cites] Oncogene. 2001 Aug 23;20(37):5239-42 [11526515.001]
  • [Cites] Am J Hum Genet. 2001 Oct;69(4):876-82 [11533913.001]
  • [Cites] Bioessays. 2001 Dec;23(12):1112-9 [11746230.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Apr;11(4):393-400 [11927500.001]
  • [Cites] Cancer Cell. 2002 Aug;2(2):157-64 [12204536.001]
  • [Cites] Nat Cell Biol. 2002 Sep;4(9):648-57 [12172553.001]
  • [Cites] Nat Cell Biol. 2002 Sep;4(9):658-65 [12172554.001]
  • [Cites] Am J Surg Pathol. 2002 Dec;26(12):1542-52 [12459621.001]
  • [Cites] J Med Genet. 2002 Dec;39(12):906-12 [12471204.001]
  • [Cites] Oncogene. 2003 May 8;22(18):2728-38 [12743597.001]
  • [Cites] Genes Dev. 2003 Aug 1;17(15):1829-34 [12869586.001]
  • [Cites] Hum Mutat. 2003 Sep;22(3):183-98 [12938083.001]
  • [Cites] Curr Biol. 2003 Nov 11;13(22):2004-8 [14614828.001]
  • [Cites] Cell. 2003 Nov 26;115(5):577-90 [14651849.001]
  • [Cites] Sci STKE. 2003 Dec 9;2003(212):re15 [14668532.001]
  • [Cites] Trends Biochem Sci. 2004 Jan;29(1):18-24 [14729328.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3329-35 [14985505.001]
  • [Cites] Oncogene. 2004 Apr 19;23(18):3151-71 [15094765.001]
  • [Cites] Genes Dev. 2004 Jul 1;18(13):1533-8 [15231735.001]
  • [Cites] Cancer Cell. 2004 Jul;6(1):7-10 [15261137.001]
  • [Cites] Cancer Cell. 2004 Jul;6(1):91-9 [15261145.001]
  • [Cites] Mod Pathol. 2004 Aug;17(8):998-1011 [15143337.001]
  • [Cites] J Cell Sci. 2004 Nov 1;117(Pt 23):5479-87 [15509864.001]
  • [Cites] Arch Dermatol. 1977 Dec;113(12):1674-7 [596896.001]
  • [Cites] Eur J Biochem. 1989 Dec 8;186(1-2):123-8 [2574667.001]
  • [Cites] Electrophoresis. 1992 Mar;13(3):142-7 [1592044.001]
  • [Cites] Rapid Commun Mass Spectrom. 1996;10(11):1371-8 [8805846.001]
  • [Cites] Nat Genet. 1998 Jan;18(1):38-43 [9425897.001]
  • [Cites] Nature. 1998 Jan 8;391(6663):184-7 [9428765.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4240-5 [10200246.001]
  • [Cites] Curr Opin Cell Biol. 1999 Apr;11(2):219-25 [10209156.001]
  • [Cites] Arch Dermatol. 1999 Oct;135(10):1195-202 [10522666.001]
  • [Cites] Curr Mol Med. 2004 Dec;4(8):813-24 [15579028.001]
  • [Cites] Nat Genet. 2005 Jan;37(1):19-24 [15624019.001]
  • [Cites] Curr Opin Cell Biol. 2005 Apr;17(2):158-66 [15780592.001]
  • [Cites] Am J Hum Genet. 2005 Jun;76(6):1023-33 [15852235.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 15;97(12):931-5 [15956655.001]
  • [Cites] Curr Opin Cell Biol. 2005 Dec;17(6):596-603 [16226444.001]
  • [Cites] Hum Genet. 2000 Aug;107(2):97-114 [11030407.001]
  • (PMID = 17028174.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Databank-accession-numbers] GENBANK/ DQ145719
  • [Grant] United States / NCI NIH HHS / CO / N01-CO-12400; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / FLCN protein, human; 0 / FNIP1 protein, human; 0 / Multienzyme Complexes; 0 / Multiprotein Complexes; 0 / Proteins; 0 / Proto-Oncogene Proteins; 0 / Tumor Suppressor Proteins; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.11.1 / AMP-Activated Protein Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  • [Other-IDs] NLM/ PMC1592464
  •  go-up   go-down


87. Vranic S, Caughron SK, Djuricic S, Bilalovic N, Zaman S, Suljevic I, Lydiatt WM, Emanuel J, Gatalica Z: Hamartomas, teratomas and teratocarcinosarcomas of the head and neck: Report of 3 new cases with clinico-pathologic correlation, cytogenetic analysis, and review of the literature. BMC Ear Nose Throat Disord; 2008;8:8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Germ-cell tumors (GCT) are a histologically and biologically diverse group of neoplasms which primarily occur in the gonads but also develop at different extragonadal sites in the midline of the body.
  • METHODS: We describe here two new cases of multilineage tumors including sinonasal teratocarcinosarcoma [SNTCS], and congenital oronasopharyngeal teratoma (epignathus) and compare their features with those of a new case of a rare salivary gland anlage tumor [SGAT], an entity for which the pathogenesis is unclear (i.e. hamartoma versus neoplasm).
  • Both cytogenetic abnormalities are characteristically present in malignant germ cell tumors providing for the first time evidence that this rare tumor type indeed might represent a variant of a germ cell neoplasm.
  • The SGAT and epignathus carried no such cytogenetic abnormalities, in keeping with their limited and benign biologic potential.
  • Malignant tumors of germ cell origins are more likely to affect adults with insidious symptom development, while benign tumors can nevertheless cause dramatic clinical symptoms which, under certain circumstances, can be fatal.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Fetal Diagn Ther. 2003 Jan-Feb;18(1):26-8 [12566771.001]
  • [Cites] Pediatrics. 2003 Jul;112(1 Pt 1):e66-9 [12837908.001]
  • [Cites] Pathol Int. 2000 Jan;50(1):71-5 [10692182.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Nov;115(1):1-10 [10565292.001]
  • [Cites] Ann Diagn Pathol. 2008 Dec;12(6):415-25 [18995206.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2008 Jun;134(6):592-5 [18559724.001]
  • [Cites] Br J Oral Maxillofac Surg. 2008 Jun;46(4):317-9 [17716791.001]
  • [Cites] Hum Pathol. 2008 Apr;39(4):605-9 [18284932.001]
  • [Cites] Zhonghua Bing Li Xue Za Zhi. 2007 Aug;36(8):534-8 [17980101.001]
  • [Cites] Br J Oral Maxillofac Surg. 2007 Jun;45(4):326-7 [16377040.001]
  • [Cites] Cancer Genet Cytogenet. 2007 Apr 1;174(1):68-73 [17350470.001]
  • [Cites] Ann Diagn Pathol. 2006 Dec;10(6):339-42 [17126251.001]
  • [Cites] J Matern Fetal Neonatal Med. 2006 Jun;19(6):377-9 [16801317.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Nov;45(11):995-1006 [16897744.001]
  • [Cites] Nat Rev Cancer. 2005 Mar;5(3):210-22 [15738984.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2005 Feb;69(2):149-56 [15656947.001]
  • [Cites] Radiographics. 2005 Jan-Feb;25(1):215-42 [15653597.001]
  • [Cites] Histopathology. 1998 Jan;32(1):84 [9522222.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Jun;25(2):134-46 [10337997.001]
  • [Cites] J Pediatr Surg. 1998 Mar;33(3):520-1 [9537572.001]
  • [Cites] Pathology. 1996 May;28(2):128-30 [8743816.001]
  • [Cites] Pathol Res Pract. 1995 Mar;191(2):166-71; discussion 172-3 [7567686.001]
  • [Cites] Cancer Genet Cytogenet. 1994 Jul 15;75(2):90-102 [8055486.001]
  • [Cites] Am J Surg Pathol. 1994 Jan;18(1):25-36 [8279626.001]
  • [Cites] Prenat Diagn. 1993 Oct;13(10):945-52 [8309901.001]
  • [Cites] Plast Reconstr Surg. 1993 Feb;91(2):223-8 [8430136.001]
  • [Cites] Acta Otorrinolaringol Esp. 1991 Sep-Oct;42(5):363-7 [1816798.001]
  • [Cites] J Laryngol Otol. 1985 Dec;99(12):1281-7 [2999276.001]
  • [Cites] Cancer. 1984 May 15;53(10):2140-54 [6322958.001]
  • [Cites] Pediatr Blood Cancer. 2004 Nov;43(6):687-91 [15390296.001]
  • [Cites] J Oral Maxillofac Surg. 2004 Mar;62(3):379-83 [15015174.001]
  • [Cites] Pediatr Surg Int. 2003 Sep;19(7):509-19 [14523568.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2002 Feb 1;62(2):159-64 [11788149.001]
  • (PMID = 19025657.001).
  • [ISSN] 1472-6815
  • [Journal-full-title] BMC ear, nose, and throat disorders
  • [ISO-abbreviation] BMC Ear Nose Throat Disord
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2611960
  •  go-up   go-down


88. Gurumurthy S, Hezel AF, Sahin E, Berger JH, Bosenberg MW, Bardeesy N: LKB1 deficiency sensitizes mice to carcinogen-induced tumorigenesis. Cancer Res; 2008 Jan 1;68(1):55-63
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lkb1 is a central regulator of cell polarity and energy metabolism through its capacity to activate the AMP-activated protein kinase (AMPK)-related family of protein kinases.
  • Germ line-inactivating mutation of Lkb1 leads to Peutz-Jeghers syndrome, which is characterized by benign hamartomas and a susceptibility to malignant epithelial tumors.
  • The basis for Lkb1-dependent tumor suppression is not defined.
  • Lkb1(+/-) mice are highly prone to DMBA-induced squamous cell carcinoma (SCC) of the skin and lung.
  • Confirming a cell autonomous tumor suppressor role of Lkb1, mice with epidermal-specific Lkb1 deletion are also susceptible to DMBA-induced SCC and develop spontaneous SCC with long latency.
  • Restoration of wild-type Lkb1 causes senescence in tumor-derived cell lines, a process that can be partially bypassed by inactivation of the Rb pathway, but not by inactivation of p53 or AMPK.
  • Our data indicate that Lkb1 is a potent suppressor of carcinogen-induced skin and lung cancers and that downstream targets beyond the AMPK-mTOR pathway are likely mediators of Lkb1-dependent tumor suppression.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3659-62 [12097271.001]
  • [Cites] Oncogene. 2007 Dec 13;26(57):7825-32 [17599048.001]
  • [Cites] Nature. 2002 Sep 12;419(6903):162-7 [12226664.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12327-32 [12218179.001]
  • [Cites] Cancer Res. 2003 Mar 15;63(6):1382-8 [12649203.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):434-43 [12778133.001]
  • [Cites] Curr Biol. 2003 Nov 11;13(22):2004-8 [14614828.001]
  • [Cites] EMBO J. 2004 Feb 25;23(4):833-43 [14976552.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3329-35 [14985505.001]
  • [Cites] Cell. 2004 Feb 6;116(3):457-66 [15016379.001]
  • [Cites] Genes Dev. 2004 Jul 1;18(13):1533-8 [15231735.001]
  • [Cites] J Biol. 2003;2(4):28 [14511394.001]
  • [Cites] Cancer Cell. 2004 Jul;6(1):91-9 [15261145.001]
  • [Cites] Carcinogenesis. 1984 May;5(5):671-82 [6327109.001]
  • [Cites] Nature. 1986 Jul 3-9;322(6074):78-80 [3014349.001]
  • [Cites] Cancer Res. 1997 Aug 1;57(15):3180-8 [9242447.001]
  • [Cites] Nat Cell Biol. 2002 Jul;4(7):487-94 [12105419.001]
  • [Cites] Curr Opin Genet Dev. 2000 Feb;10(1):106-13 [10679397.001]
  • [Cites] Cell. 2000 Jul 21;102(2):211-20 [10943841.001]
  • [Cites] Nature. 2001 Sep 6;413(6851):86-91 [11544531.001]
  • [Cites] Horm Res. 2000;54(5-6):296-300 [11595821.001]
  • [Cites] Oncogene. 2002 Jan 3;21(1):53-64 [11791176.001]
  • [Cites] Cancer Res. 2002 Apr 15;62(8):2261-6 [11956081.001]
  • [Cites] Hum Mol Genet. 2002 Jun 15;11(13):1497-504 [12045203.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8903-8 [12060709.001]
  • [Cites] Nat Genet. 1998 Jan;18(1):38-43 [9425897.001]
  • [Cites] Genes Dev. 1998 Aug 15;12(16):2469-74 [9716400.001]
  • [Cites] Cell Mol Life Sci. 1999 May;55(5):735-50 [10379360.001]
  • [Cites] J Cell Biol. 2004 Nov 8;167(3):399-403 [15533996.001]
  • [Cites] Semin Cell Dev Biol. 2005 Feb;16(1):29-37 [15659337.001]
  • [Cites] Am J Gastroenterol. 2005 Feb;100(2):476-90 [15667510.001]
  • [Cites] Trends Pharmacol Sci. 2005 Feb;26(2):69-76 [15681023.001]
  • [Cites] Science. 2005 Dec 9;310(5754):1642-6 [16308421.001]
  • [Cites] Gut. 2006 Jan;55(1):1-5 [16344569.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):3209-15 [16707622.001]
  • [Cites] Mol Cell Biol. 2006 Nov;26(22):8217-27 [16966378.001]
  • [Cites] Curr Opin Cell Biol. 2006 Dec;18(6):598-608 [17046224.001]
  • [Cites] Cancer Cell. 2006 Dec;10(6):459-72 [17157787.001]
  • [Cites] Genes Dev. 2007 Jan 1;21(1):1-5 [17210783.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):819-22 [17204563.001]
  • [Cites] Cell. 2007 Jan 26;128(2):233-4 [17254959.001]
  • [Cites] Oncogene. 2007 Mar 8;26(11):1616-25 [16953221.001]
  • [Cites] Cell. 2007 May 4;129(3):549-63 [17482548.001]
  • [Cites] Cell. 2007 May 4;129(3):565-77 [17482549.001]
  • [Cites] J Cell Biol. 2007 May 7;177(3):387-92 [17470638.001]
  • [Cites] Nature. 2007 Jun 21;447(7147):1017-20 [17486097.001]
  • [Cites] Nature. 2007 Aug 16;448(7155):807-10 [17676035.001]
  • [Cites] Oncogene. 2007 Aug 30;26(40):5911-8 [17384680.001]
  • [ErratumIn] Cancer Res. 2008 Apr 1;68(7):2549. Sahin, Ergun [added]
  • (PMID = 18172296.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K01 CA104647; United States / NCI NIH HHS / CA / P01 CA117969; United States / NCI NIH HHS / CA / 5 K01 CA104647; United States / NCI NIH HHS / CA / 5 P01 CA117969
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Retinoblastoma Protein; 0 / Tumor Suppressor Protein p53; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene; EC 2.7.1.- / Stk11 protein, mouse; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  • [Other-IDs] NLM/ NIHMS171049; NLM/ PMC3739055
  •  go-up   go-down


89. Shi Y, Liu Z, Peng Z, Liu H, Yang K, Yao X: The diagnosis and treatment of Mullerian adenosarcoma of the uterus. Aust N Z J Obstet Gynaecol; 2008 Dec;48(6):596-600
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Patients typically presented with abnormal uterine bleeding, pain in the lower abdomen, enlargement of the uterus, a mass in the uterine cavity and/or a cervical neoplasm.
  • Microscopically, the glands were lined by benign or atypical glandular epithelium, together with sarcomatous stromal cells which showed characteristic structures of 'periglandular cuff' of increased cellularity and 'intraglandular polypoid projections'.
  • [MeSH-major] Adenosarcoma / diagnosis. Mixed Tumor, Mullerian / diagnosis. Neoplasms, Germ Cell and Embryonal / diagnosis. Uterine Cervical Neoplasms / diagnosis. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Adult. Age Factors. Diagnosis, Differential. Female. Humans. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19133051.001).
  • [ISSN] 1479-828X
  • [Journal-full-title] The Australian & New Zealand journal of obstetrics & gynaecology
  • [ISO-abbreviation] Aust N Z J Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


90. Leiserowitz GS: Managing ovarian masses during pregnancy. Obstet Gynecol Surv; 2006 Jul;61(7):463-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The etiologies of ovarian masses are reflective of the patient's age; and, therefore, benign entities such as functional ovarian cysts, benign cystic teratomas, and serous cystadenomas predominate.
  • In the unusual cases when cancer is present, they are typically germ cell and borderline ovarian tumors, and are commonly low stage and low grade.
  • Morphologic criteria more accurately identify benign cysts compared with malignant tumors.
  • Tumor markers are used primarily to monitor disease status after treatment rather than establish the ovarian tumor diagnosis as a result of lack of specificity, because several markers can be elevated inherent to the pregnancy itself (eg, CA-125, beta-hCG).
  • The extent of surgery depends on the intraoperative diagnosis of a benign versus a malignant tumor.
  • Conservative surgery is appropriate for benign masses and borderline ovarian tumors.
  • [MeSH-minor] Female. Humans. Laparoscopy / methods. Neoplasm Staging. Pregnancy. Pregnancy Outcome. Prognosis. Risk Factors. Sensitivity and Specificity


91. Bandarchi B, Ma L, Marginean C, Hafezi S, Zubovits J, Rasty G: D2-40, a novel immunohistochemical marker in differentiating dermatofibroma from dermatofibrosarcoma protuberans. Mod Pathol; 2010 Mar;23(3):434-8
Genetic Alliance. consumer health - Dermatofibrosarcoma Protuberans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • D2-40 identifies a 40-kDa O-linked sialoglycoprotein present on a variety of tissues including testicular germ cell tumors as well as lymphatic endothelium.
  • [MeSH-major] Antibodies, Monoclonal / analysis. Biomarkers, Tumor / analysis. Dermatofibrosarcoma / diagnosis. Histiocytoma, Benign Fibrous / diagnosis

  • Genetic Alliance. consumer health - Dermatofibroma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20062007.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 0 / monoclonal antibody D2-40; EC 2.3.2.13 / Factor XIIIa
  •  go-up   go-down


92. Kline RC, Bazzett-Matabele LB: Adnexal masses and malignancies of importance to the colorectal surgeon. Clin Colon Rectal Surg; 2010 Jun;23(2):63-71

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this article, the authors review both benign and malignant ovarian masses, as the colorectal surgeon who encounters an adnexal mass at the time of surgery should be aware of the steps necessary for surgical staging and optimal tumor resection.Ovarian tumors-most of which are benign-are divided into three major categories, in order of frequency: epithelial, germ cell, and sex cord-stromal tumors.
  • Nonneoplastic conditions of the ovary that may present as adnexal masses include the following, according to World Health Organization (WHO) classification: pregnancy luteoma, hyperplasia of ovarian stroma, hyperthecosis, massive edema, solitary follicle cysts and corpus luteal cysts, multiple follicle cysts, and endometriosis.Epithelial ovarian tumors arise from the surface epithelium and can be benign or malignant.
  • Histologic types are serous, mucinous, endometrioid, clear cell, or Brenner.
  • Germ cell tumors are more likely to appear in females under 20 years, accounting for 70% of ovarian tumors in this age group.
  • Teratomas are the most common germ cell tumors.
  • The more common sex cord-stromal tumors include granulosa stromal cell tumors, Sertoli-Leydig cell tumors, and gynandroblastomas.Surgical staging and optimal tumor resection are also addressed, with a focus on epithelial malignancies, as they are the most relevant to colorectal surgeons.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2001 Apr;81(1):77-81 [11277654.001]
  • [Cites] JAMA. 1983 Dec 9;250(22):3072-6 [6358558.001]
  • [Cites] Am J Obstet Gynecol. 2005 Jul;193(1):30-5 [16021055.001]
  • [Cites] Gynecol Oncol. 2006 Jan;100(1):185-91 [16216320.001]
  • [Cites] N Engl J Med. 2006 Jan 5;354(1):34-43 [16394300.001]
  • [Cites] Gynecol Oncol. 2006 Nov;103(2):383-90 [17005244.001]
  • [Cites] Obstet Gynecol. 2009 Apr;113(4):775-82 [19305319.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Int J Gynecol Pathol. 1990;9(4):343-51 [2246093.001]
  • [Cites] Curr Top Pathol. 1989;78:85-109 [2651026.001]
  • [Cites] Environ Health Perspect. 1987 Aug;73:15-25 [3665859.001]
  • [Cites] Obstet Gynecol. 1983 Apr;61(4):413-20 [6828269.001]
  • [Cites] Gynecol Oncol. 1989 Nov;35(2):139-44 [2680797.001]
  • [Cites] Obstet Gynecol. 1989 Dec;74(6):921-6 [2685680.001]
  • [Cites] J Clin Oncol. 1988 Jun;6(6):983-9 [3373267.001]
  • [Cites] Gynecol Oncol. 2002 Jul;86(1):34-7 [12079297.001]
  • (PMID = 21629623.001).
  • [ISSN] 1530-9681
  • [Journal-full-title] Clinics in colon and rectal surgery
  • [ISO-abbreviation] Clin Colon Rectal Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2967325
  • [Keywords] NOTNLM ; Adnexal masses / ovarian cancer / ovarian cysts
  •  go-up   go-down


93. Cofield KR 3rd, Cantley LK, Geisinger KR, Zagoria RJ, Perrier ND: Adrenocortical carcinoma arising from a long-standing adrenal mass. Mayo Clin Proc; 2005 Feb;80(2):264-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adrenocortical carcinoma is a rare tumor with a dismal prognosis.
  • In stark contrast, benign incidental adrenal lesions are detected commonly on routine abdominal imaging.
  • We report a case of a 74-year-old man with a history of germ cell testicular carcinoma who presented with a 4.8-cm left adrenal lesion.
  • [MeSH-minor] Aged. Cell Transformation, Neoplastic. Fatal Outcome. Humans. Male. Time Factors

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15704782.001).
  • [ISSN] 0025-6196
  • [Journal-full-title] Mayo Clinic proceedings
  • [ISO-abbreviation] Mayo Clin. Proc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Ben Temime R, Chachial A, Attial L, Ghodbanel I, Makhloufl T, Koubaal A, Kourda N, Ben Jilani S, Dammak T, El May A, Rahal K: 46 XY pure gonadal dysgenesis with gonadoblastoma and dysgerminoma. Tunis Med; 2008 Jul;86(7):710-3
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor that usually develops in Swyer syndrome is gonadoblastoma.
  • Although gonadoblastoma is considered benign, the risk of malignant germ cell tumor development is high.
  • OBJECTIVE: The aim of this report is to stress on the risk of occurrence of malignant germ cell tumors on these dysgenesic gonads.

  • Genetic Alliance. consumer health - Gonadal Dysgenesis.
  • Genetic Alliance. consumer health - Swyer syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19472738.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


95. Beeker A, Boven E, Lefesvre P, Golding R, van Groeningen CJ: Retroperitoneal mature teratoma after orchidectomy for a stage IB pure embryonal testicular carcinoma. Int J Clin Oncol; 2008 Feb;13(1):71-3
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nonseminomatous germ cell tumor of the testis stage I will relapse in approximately 30% of patients in the first year after orchidectomy.
  • Our patient had an unusual case of metastasis formation of benign histology of a previously removed highly malignant primary tumor confined to the testis.

  • Genetic Alliance. consumer health - Embryonal Carcinoma.
  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Urol. 2001 Apr;19(2):76-81 [11374321.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1294-9 [8391067.001]
  • [Cites] J Clin Oncol. 2006 Dec 10;24(35):5493-502 [17158534.001]
  • [Cites] Crit Rev Oncol Hematol. 2005 Feb;53(2):141-64 [15661565.001]
  • [Cites] J Clin Oncol. 2006 Dec 10;24(35):5482-92 [17158533.001]
  • [Cites] J Urol. 1997 Jan;157(1):160-3 [8976241.001]
  • [Cites] Cancer. 1995 May 1;75(9):2244-50 [7712432.001]
  • [Cites] Urology. 2003 Dec;62(6):1092-6 [14665362.001]
  • [Cites] Eur J Cancer. 2000 Jul;36(11):1389-94 [10899652.001]
  • (PMID = 18307023.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


96. Trousse D, Avaro JP: [Mediastinal tumors: introduction]. Rev Pneumol Clin; 2010 Feb;66(1):3-16

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mediastinal masses represent a group of heterogeneous histological type cell.
  • A definite diagnosis is essential leading to an adequate prompt therapeutic strategy when either benign disease or aggressive malignant tumor is conceivable.
  • However the specific diagnosis could be complex and requires histological confirmation by an experienced pathologist after examination of large biopsies of the tumor.
  • [MeSH-minor] Adult. Diagnosis, Differential. Goiter / diagnosis. Goiter / pathology. Goiter / surgery. Humans. Lymph Node Excision. Lymphatic Metastasis / pathology. Lymphoma / diagnosis. Lymphoma / pathology. Lymphoma / surgery. Mediastinoscopy. Mediastinum / pathology. Mediastinum / surgery. Neoplasms, Germ Cell and Embryonal / diagnosis. Neoplasms, Germ Cell and Embryonal / pathology. Neoplasms, Germ Cell and Embryonal / surgery. Thoracotomy. Thymoma / diagnosis. Thymoma / pathology. Thymoma / surgery. Thymus Neoplasms / diagnosis. Thymus Neoplasms / pathology. Thymus Neoplasms / surgery. Tomography, X-Ray Computed. Video Recording. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20207291.001).
  • [ISSN] 0761-8417
  • [Journal-full-title] Revue de pneumologie clinique
  • [ISO-abbreviation] Rev Pneumol Clin
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 40
  •  go-up   go-down


97. Khonsari RH: [Jaw tumors of embryonic origin]. Rev Stomatol Chir Maxillofac; 2009 Sep;110(4):214-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The term jaw tumor of embryonic origin includes vestiges of organogenetic processes, hamartomas, teratomas, and blastemal tumors.
  • Oral cavity teratomas are almost always mature and thus benign and encapsulated.
  • It can be immediate postbirth tumor removal when neonatal respiratory distress can be managed by the anesthesiologist, or an EXIT (ex utero intrapartum) procedure.
  • [MeSH-major] Jaw Neoplasms / diagnosis. Neoplasms, Germ Cell and Embryonal / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19647282.001).
  • [ISSN] 1776-257X
  • [Journal-full-title] Revue de stomatologie et de chirurgie maxillo-faciale
  • [ISO-abbreviation] Rev Stomatol Chir Maxillofac
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


98. Lemeta S, Salmenkivi K, Pylkkänen L, Sainio M, Saarikoski ST, Arola J, Heikkilä P, Haglund C, Husgafvel-Pursiainen K, Böhling T: Frequent loss of heterozygosity at 6q in pheochromocytoma. Hum Pathol; 2006 Jun;37(6):749-54
MedlinePlus Health Information. consumer health - Pheochromocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most PCCs are sporadic, but they also occur in inherited tumor syndromes, including von Hippel-Lindau disease.
  • Mutations of those genes that harbor germ-line mutations in familial cases cover only 10% to 15% of somatic mutations in sporadic PCCs.
  • We therefore investigated in detail 18 PCCs using 22 microsatellite markers spanning 6q to search for the presence of allele deletions and identify specific regions likely to contain tumor suppressor genes involved in PCC.
  • Moreover, we sought to compare PCC with capillary hemangioblastoma, another von Hippel-Lindau disease-associated tumor that we previously found to harbor frequent loss of heterozygosity (LOH) at 6q.
  • Loss of heterozygosity at 6q was observed in 6 benign (6/9; 67%) and 7 borderline (7/9; 78%) tumors.
  • Similar to our findings for capillary hemangioblastomas, our data for the first time suggest that one or several tumor suppressor genes located at 6q, particularly at 6q23-24, may play a role in the tumorigenesis of PCCs.
  • [MeSH-major] Allelic Imbalance. Cell Cycle Proteins / genetics. Chromosomes, Human, Pair 6. Loss of Heterozygosity. Pheochromocytoma / genetics. Transcription Factors / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adult. Aged. Alleles. DNA, Neoplasm / analysis. Female. Gene Deletion. Genetic Markers. Hemangioblastoma / genetics. Hemangioblastoma / pathology. Humans. Male. Microsatellite Repeats. Middle Aged. Tumor Burden

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16733217.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / DNA, Neoplasm; 0 / Genetic Markers; 0 / PLAGL1 protein, human; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


99. De Moura J, Kavalec FL, Doghman M, Rosati R, Custodio G, Lalli E, Cavallari GM, Santa Maria J, Figueiredo BC: Heterozygous TP53stop146/R72P fibroblasts from a Li-Fraumeni syndrome patient with impaired response to DNA damage. Int J Oncol; 2010 Apr;36(4):983-90
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In order to investigate the disruption of the p53 function in a patient presenting this mutation and the TP53Arg72Pro polymorphism who had so far suffered five malignant tumors and a benign meningioma, we tested her fibroblasts in response to DNA damage by evaluating the proliferation rate, apoptosis, and disruption of the TP53 pathway.
  • The proband's heterozygous fibroblasts were not as efficient as control fibroblasts or those of her mother, who carried only the TP53Arg72Pro polymorphism, in causing cell arrest and cell death after DNA damage, which was correlated with diminished TP21 protein levels.
  • [MeSH-major] Codon, Nonsense. DNA Damage. Fibroblasts / metabolism. Germ-Line Mutation. Li-Fraumeni Syndrome / genetics. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Adult. Antineoplastic Agents, Phytogenic / pharmacology. Apoptosis. Cell Cycle. Cell Proliferation. Cells, Cultured. Codon, Terminator. Cyclin-Dependent Kinase Inhibitor p21 / metabolism. Etoposide / pharmacology. Female. Genotype. Heterozygote. Humans. Male. Middle Aged. Pedigree. Phenotype. Polymorphism, Genetic

  • Genetic Alliance. consumer health - Li Fraumeni syndrome.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20198344.001).
  • [ISSN] 1791-2423
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / CDKN1A protein, human; 0 / Codon, Nonsense; 0 / Codon, Terminator; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 6PLQ3CP4P3 / Etoposide
  •  go-up   go-down


100. Bologna-Molina R, Mosqueda-Taylor A, Lopez-Corella E, Almeida OP, Carrasco-Daza D, Garcia-Vazquez F, Farfan-Morales JE, Irigoyen-Camacho ME, Damián-Matsumura P: Syndecan-1 (CD138) and Ki-67 expression in different subtypes of ameloblastomas. Oral Oncol; 2008 Aug;44(8):805-11

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ameloblastoma is the most frequent odontogenic tumor and is considered a benign, but locally invasive, neoplasm with variable clinico-pathological expression.
  • Syndecan-1 is a cell surface proteoglycan that binds cells to the extracellular matrix and its expression is down-regulated in many cellular transformation models.
  • [MeSH-major] Ameloblastoma / metabolism. Ki-67 Antigen / metabolism. Neoplasm Proteins / metabolism. Syndecan-1 / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Down-Regulation. Female. Gene Expression. Humans. Immunohistochemistry. Male. Middle Aged. Mouth Mucosa / metabolism. Tooth Germ / metabolism. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18207448.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Neoplasm Proteins; 0 / Syndecan-1
  •  go-up   go-down






Advertisement